<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>TmmGeek</title>
    <description>A reserved &lt;a href=&quot;http://jekyllrb.com&quot; target=&quot;_blank&quot;&gt;Jekyll&lt;/a&gt; theme that places the utmost gravity on content with a hidden drawer. Made by &lt;a href=&quot;https://twitter.com/mdo&quot; target=&quot;_blank&quot;&gt;@mdo&lt;/a&gt;.</description>
    <link>http://lanyon.getpoole.com/</link>
    <atom:link href="http://lanyon.getpoole.com/feed.xml" rel="self" type="application/rss+xml"/>
    <pubDate>Mon, 30 Nov 2015 10:14:31 -0600</pubDate>
    <lastBuildDate>Mon, 30 Nov 2015 10:14:31 -0600</lastBuildDate>
    <generator>Jekyll v2.5.3</generator>
    
      <item>
        <title>Linear Algebra study note</title>
        <description>&lt;ul id=&quot;markdown-toc&quot;&gt;
  &lt;li&gt;&lt;a href=&quot;#definition-of-mathbf-rn-and-mathbf-r&quot; id=&quot;markdown-toc-definition-of-mathbf-rn-and-mathbf-r&quot;&gt;Definition of &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^n&lt;/script&gt; and &lt;script type=&quot;math/tex&quot;&gt;\mathbf R&lt;/script&gt;&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#vector-transformation&quot; id=&quot;markdown-toc-vector-transformation&quot;&gt;vector transformation&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#formal-understanding-of-functions&quot; id=&quot;markdown-toc-formal-understanding-of-functions&quot;&gt;Formal understanding of functions&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#the-concept-of-linear-independance&quot; id=&quot;markdown-toc-the-concept-of-linear-independance&quot;&gt;The concept of Linear independance&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#test-of-linear-dependance&quot; id=&quot;markdown-toc-test-of-linear-dependance&quot;&gt;Test of linear dependance&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#example-1&quot; id=&quot;markdown-toc-example-1&quot;&gt;Example 1&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#example-3&quot; id=&quot;markdown-toc-example-3&quot;&gt;example 3&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#parametric-representation-of-lines&quot; id=&quot;markdown-toc-parametric-representation-of-lines&quot;&gt;Parametric representation of lines&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#dimension-of-the-column-space-or-rank&quot; id=&quot;markdown-toc-dimension-of-the-column-space-or-rank&quot;&gt;Dimension of the Column Space or Rank&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#linear-subspaces&quot; id=&quot;markdown-toc-linear-subspaces&quot;&gt;Linear subspaces&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#a-trival-example-in-mathbf-r3&quot; id=&quot;markdown-toc-a-trival-example-in-mathbf-r3&quot;&gt;a trival example in &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^3&lt;/script&gt;&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#example-2&quot; id=&quot;markdown-toc-example-2&quot;&gt;example 2&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#example-3-1&quot; id=&quot;markdown-toc-example-3-1&quot;&gt;example 3&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#basis&quot; id=&quot;markdown-toc-basis&quot;&gt;Basis&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#example-1-1&quot; id=&quot;markdown-toc-example-1-1&quot;&gt;example 1&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#dot-product&quot; id=&quot;markdown-toc-dot-product&quot;&gt;Dot product&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#definition&quot; id=&quot;markdown-toc-definition&quot;&gt;definition&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#vector-into-components-projection&quot; id=&quot;markdown-toc-vector-into-components-projection&quot;&gt;vector into components: projection&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;!--break--&gt;

&lt;h2 id=&quot;definition-of-mathbf-rn-and-mathbf-r&quot;&gt;Definition of &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^n&lt;/script&gt; and &lt;script type=&quot;math/tex&quot;&gt;\mathbf R&lt;/script&gt;&lt;/h2&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec X \in \mathbf R^n&lt;/script&gt;

&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;\mathbf R^n = \begin{cases}
n-tuple\\
(x_1,x_2 \cdots x_n)\end{cases}&lt;/script&gt;
&lt;script type=&quot;math/tex&quot;&gt;\bigr| x_1,x_2,\cdots x_n \in \mathbf R&lt;/script&gt;&lt;/p&gt;

&lt;h2 id=&quot;vector-transformation&quot;&gt;vector transformation&lt;/h2&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec x = \begin{bmatrix}
	x_1\\
	x_2\\
	\vdots\\
	x_n
	\end{bmatrix}
	\vec y = \begin{bmatrix}
	y_1\\
	y_2\\
	\vdots\\
	y_m
	\end{bmatrix}&lt;/script&gt;

&lt;p&gt;let &lt;script type=&quot;math/tex&quot;&gt;\vec x \in \mathbf R^n \text{and} \vec y \in \mathbf R^m&lt;/script&gt;&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;f:\mathbf R^n \implies \mathbf R^m&lt;/script&gt;

&lt;p&gt;for example&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;f:\mathbf R^3 \implies \mathbf R^2&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\begin{bmatrix}
	x_1\\
	x_2\\
	x_3\\
	\end{bmatrix}
	=
	\begin{bmatrix}
	x_1+2x_2\\
	3x_3\\
	\end{bmatrix}&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\begin{bmatrix}
	1\\
	1\\
	1\\
	\end{bmatrix}
	=
	\begin{bmatrix}
	3\\
	3\\
	\end{bmatrix}&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\begin{bmatrix}
	2\\
	4\\
	1\\
	\end{bmatrix}
	=
	\begin{bmatrix}
	10\\
	3\\
	\end{bmatrix}&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;T:\mathbf R^3 \implies\mathbf R^2&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;T(x_1,x_2,x_3) \implies (x_1+2x_2, 3x_3)&lt;/script&gt;

&lt;h2 id=&quot;formal-understanding-of-functions&quot;&gt;Formal understanding of functions&lt;/h2&gt;

&lt;p&gt;if a function g(x) maps the single number 2.&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;g(x_1,x_2) = 2&lt;/script&gt;

&lt;p&gt;Then, the domain is &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^2&lt;/script&gt; and the codomain is &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^3&lt;/script&gt; but the range is 2.&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;h:\mathbf R^2 \implies \mathbf R^3&lt;/script&gt;

&lt;p&gt;In this, the domain is &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^2&lt;/script&gt; and the codomain and the range are &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^3&lt;/script&gt;, for example&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf h (x_1,x_2) = (x_1+x_2, x_2-x_1,x_2x_1)&lt;/script&gt;

&lt;h2 id=&quot;the-concept-of-linear-independance&quot;&gt;The concept of Linear independance&lt;/h2&gt;

&lt;p&gt;The main idea is that there is no redundent vectors in the space&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;c_1\vec v_1+c_2\vec v_2 + \cdots c_n\vec v_n = \mathbf 0| c_1=c_2 \cdots c_n = 0&lt;/script&gt;

&lt;p&gt;&lt;a href=&quot;https://www.khanacademy.org/math/linear-algebra/vectors_and_spaces/linear_independence/v/span-and-linear-independence-example&quot;&gt;see&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;test-of-linear-dependance&quot;&gt;Test of linear dependance&lt;/h3&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;s = \{\vec v_1 \vec v_2, \cdots\vec v_n\} \iff c_1\vec v_1 + c_2\vec v_2 \cdots c_n\vec v_n = \mathbf 0&lt;/script&gt;

&lt;p&gt;For some &lt;script type=&quot;math/tex&quot;&gt;c_i&lt;/script&gt;, not all are 0. (at least 1 is non-zero)&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/linear%20algebra/2015/11/18/proof-linear-algebra/#linear_dependence&quot;&gt;see proof&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;example-1&quot;&gt;Example 1&lt;/h3&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\left( \mathbf A =
\begin{bmatrix}
2\\
1\\
\end{bmatrix}
,
\mathbf B =
\begin{bmatrix}
2\\
1\\
\end{bmatrix}
\right)&lt;/script&gt;

&lt;p&gt;to test if A and B are independent&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;c_1
\begin{bmatrix}
2\\
1\\
\end{bmatrix}
+ c_2
\begin{bmatrix}
2\\
1\\
\end{bmatrix}
= 0&lt;/script&gt;

&lt;p&gt;To satisify the conditon above, if either &lt;script type=&quot;math/tex&quot;&gt;c_1&lt;/script&gt; or &lt;script type=&quot;math/tex&quot;&gt;c_2&lt;/script&gt; are non-zero, then A and B are dependent 
If both &lt;script type=&quot;math/tex&quot;&gt;c_1,c_2&lt;/script&gt; are 0, then A and B are independent&lt;/p&gt;

&lt;p&gt;adapted from &lt;a href=&quot;https://www.khanacademy.org/math/linear-algebra/vectors_and_spaces/linear_independence/v/more-on-linear-independence&quot;&gt;Khanacademy&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;example-3&quot;&gt;example 3&lt;/h3&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\left(\begin{bmatrix}
1\\
-1\\
2\\
\end{bmatrix},

\begin{bmatrix}
1\\
1\\
3
\end{bmatrix}
,
\begin{bmatrix}
-1\\
0\\
2\\
\end{bmatrix}\right)
 = \mathbf Span(s) \ = \mathbf R^3?&lt;/script&gt;

&lt;h2 id=&quot;parametric-representation-of-lines&quot;&gt;Parametric representation of lines&lt;/h2&gt;

&lt;!--break--&gt;
&lt;p&gt;let &lt;script type=&quot;math/tex&quot;&gt;\vec V = \begin{bmatrix}
		2\\
        1\\
\end{bmatrix}&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;then the span is 
&lt;script type=&quot;math/tex&quot;&gt;\ \mathbf S = \{ c\vec V | c \in \mathbf R \}&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;let &lt;script type=&quot;math/tex&quot;&gt;\vec X = \begin{bmatrix}
			2\\
			4\\	
			\end{bmatrix}&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;To find a line passes through &lt;script type=&quot;math/tex&quot;&gt;\vec X&lt;/script&gt;  and parellel to &lt;script type=&quot;math/tex&quot;&gt;\vec V&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;we can use this formula&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;L =\{\vec X + t\vec V| t\in \mathbf R\}&lt;/script&gt;

&lt;p&gt;To find a line passes through both &lt;script type=&quot;math/tex&quot;&gt;\vec a and \vec b&lt;/script&gt;, use either&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;L = \{\vec b + t(\vec b-\vec a| t \in \mathbf R)\}&lt;/script&gt;

&lt;p&gt;or&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;L = \{\vec a + t(\vec b-\vec a| t \in \mathbf R)\}&lt;/script&gt;

&lt;p&gt;example&lt;/p&gt;

&lt;p&gt;let &lt;script type=&quot;math/tex&quot;&gt;\vec a = \begin{bmatrix}
			2\\
			1\\
			\end{bmatrix}&lt;/script&gt;
	  &lt;script type=&quot;math/tex&quot;&gt;\vec b = \begin{bmatrix}
	  		0\\
			3\\
			\end{bmatrix}&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;then &lt;script type=&quot;math/tex&quot;&gt;L = \{\begin{bmatrix}
			2\\
			1\\
			\end{bmatrix} + t(\begin{bmatrix}
			0\\
			3\\
			\end{bmatrix}
			-\begin{bmatrix}
			2\\
			1\\
			\end{bmatrix}) | t\in \mathbf R\}&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;To see full from this video&lt;/p&gt;

&lt;p&gt;&lt;a style=&quot;color: #111; font-family: helvetica;&quot; target=&quot;_blank&quot; href=&quot;https://www.khanacademy.org/video/linear-algebra-parametric-representations-of-lines?utm_campaign=embed&quot;&gt;&lt;/a&gt;&lt;/p&gt;
&lt;iframe frameborder=&quot;0&quot; scrolling=&quot;no&quot; width=&quot;560&quot; height=&quot;355&quot; src=&quot;https://www.khanacademy.org/embed_video?v=hWhs2cIj7Cw&quot; allowfullscreen=&quot;&quot; webkitallowfullscreen=&quot;&quot; mozallowfullscreen=&quot;&quot;&gt;&lt;/iframe&gt;

&lt;h2 id=&quot;dimension-of-the-column-space-or-rank&quot;&gt;Dimension of the Column Space or Rank&lt;/h2&gt;

&lt;p&gt;The following is adapted from &lt;a href=&quot;https://www.khanacademy.org/math/linear-algebra/vectors_and_spaces/null_column_space/v/dimension-of-the-column-space-or-rank&quot;&gt;Khanacademy&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a style=&quot;color: #111; font-family: helvetica;&quot; target=&quot;_blank&quot; href=&quot;https://www.khanacademy.org/video/dimension-of-the-column-space-or-rank?utm_campaign=embed&quot;&gt;&lt;/a&gt;&lt;/p&gt;

&lt;iframe frameborder=&quot;0&quot; scrolling=&quot;no&quot; width=&quot;560&quot; height=&quot;355&quot; src=&quot;https://www.khanacademy.org/embed_video?v=JUgrBkPteTg&quot; allowfullscreen=&quot;&quot; webkitallowfullscreen=&quot;&quot; mozallowfullscreen=&quot;&quot;&gt;&lt;/iframe&gt;

&lt;p&gt;Rank is the dimension of the basis of a matrix.&lt;/p&gt;

&lt;p&gt;In order to be a basis, it has to satisfy that&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;vectors span &lt;script type=&quot;math/tex&quot;&gt;\mathbf A&lt;/script&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;all the column vectors of a basis are linear independent&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;for example&lt;/p&gt;
&lt;p align=&quot;right&quot;&gt;(1)&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;% &lt;![CDATA[
\mathbf A = \begin{bmatrix}
        1 &amp; 0 &amp; -1 &amp; 0 &amp; 4 \\
        2 &amp; 1 &amp; 0 &amp; 0 &amp; 9 \\
        -1 &amp; 2 &amp; 5 &amp; 1 &amp; -5 \\
        1 &amp; -1 &amp; -3 &amp; -2 &amp; 9
        \end{bmatrix} %]]&gt;&lt;/script&gt;

&lt;p&gt;the column space of &lt;script type=&quot;math/tex&quot;&gt;\mathbf A&lt;/script&gt; is&lt;/p&gt;

&lt;p align=&quot;right&quot;&gt;(2)&lt;/p&gt;
&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;C(\mathbf A) = span\{\vec a_1,\vec a_2,\vec a_3,\vec a_4, \vec a_5\}&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;However, we don’t know if all the  column vectors in the span are linear independant&lt;/p&gt;

&lt;p&gt;To find the basis, let’s convert to reduced echelon form &lt;script type=&quot;math/tex&quot;&gt;A_e&lt;/script&gt;&lt;/p&gt;
&lt;p align=&quot;right&quot;&gt;(3)&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;% &lt;![CDATA[
\mathbf A_e = \begin{bmatrix}
        1 &amp; 0 &amp; -1 &amp; 0 &amp; 4 \\
        0 &amp; 1 &amp; 2 &amp; 0 &amp; 1 \\
        0 &amp; 0 &amp; 0 &amp; 1 &amp; -3 \\
        0 &amp; 0 &amp; 0 &amp; 0 &amp; 0
        \end{bmatrix} %]]&gt;&lt;/script&gt;

&lt;p&gt;let &lt;script type=&quot;math/tex&quot;&gt;\vec r_i&lt;/script&gt; denote the columns of A&lt;/p&gt;
&lt;p align=&quot;right&quot;&gt;(4)&lt;/p&gt;

&lt;p&gt;we see that &lt;script type=&quot;math/tex&quot;&gt;\{\vec r_1,\vec r_3,\vec r_4\}&lt;/script&gt; are linear independent and for the basis of &lt;script type=&quot;math/tex&quot;&gt;\mathbf A_e&lt;/script&gt;, and the 1s in these column vectors are also called the &lt;a href=&quot;https://en.wikibooks.org/wiki/Linear_Algebra/Row_Reduction_and_Echelon_Forms#Pivot_Positions&quot;&gt;pivot entries&lt;/a&gt;. Moreover, &lt;script type=&quot;math/tex&quot;&gt;\{\vec r_3,\vec r_5\}&lt;/script&gt; can be represented as linear combinations of &lt;script type=&quot;math/tex&quot;&gt;\{\vec r_1,\vec r_2,\vec r_4\}&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;Therefore, we can conclude that  &lt;script type=&quot;math/tex&quot;&gt;\{\vec a_1,\vec a_2,\vec a_4,\} in \mathbf A&lt;/script&gt; are also linear independent and they are the basis of &lt;script type=&quot;math/tex&quot;&gt;\mathbf A&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;And the Rank of A is just the dimension of the basis, so &lt;script type=&quot;math/tex&quot;&gt;rank(\mathbf A) = 3&lt;/script&gt;&lt;/p&gt;

&lt;h2 id=&quot;linear-subspaces&quot;&gt;Linear subspaces&lt;/h2&gt;

&lt;p&gt;In order to be a subspace, a set must satisfy the following 3 criterias&lt;/p&gt;

&lt;p&gt;let&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf R^n \leftarrow \left( 
\begin{bmatrix}
x_1\\
x_2\\
\vdots\\
x_n
\end{bmatrix} | x_i \in \mathbf R \ 1\le i \le n
\right)&lt;/script&gt;

&lt;p&gt;Let’s assume &lt;script type=&quot;math/tex&quot;&gt;\mathbf V&lt;/script&gt; is a subspace of &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^n&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;then&lt;/p&gt;

&lt;p&gt;1:&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf V \ contains  \ \mathbf 0 = \begin{bmatrix}
0\\
\vdots\\
0
\end{bmatrix}&lt;/script&gt;

&lt;p&gt;2:&lt;/p&gt;

&lt;p&gt;And if &lt;script type=&quot;math/tex&quot;&gt;\vec x \in \mathbf V \ \text{then} \ c\vec x \ \ also \ in \mathbf V&lt;/script&gt;
This is defined as closure under scalar multiplication&lt;/p&gt;

&lt;p&gt;3:&lt;/p&gt;

&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;\vec a \in \mathbf V \ and \ \vec b \ \in \mathbf V, \ then \ \vec a + \vec b \ is \ also \ in \mathbf V&lt;/script&gt;
This is defined as closure under addition&lt;/p&gt;

&lt;h3 id=&quot;a-trival-example-in-mathbf-r3&quot;&gt;a trival example in &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^3&lt;/script&gt;&lt;/h3&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf V \ = \ {\mathbf 0} = \begin{bmatrix}
0\\
0\\
0\\
\end{bmatrix}&lt;/script&gt;

&lt;p&gt;it satisifies the 3 criterias&lt;/p&gt;

&lt;p&gt;1: it contains the zero vector.&lt;/p&gt;

&lt;p&gt;2: when it is multiplied by any real number scalar c, it is still itself. This implies it is still a member of &lt;script type=&quot;math/tex&quot;&gt;\mathbf 
R^3&lt;/script&gt; and satisify closure under multiplication&lt;/p&gt;

&lt;p&gt;3: when &lt;script type=&quot;math/tex&quot;&gt;\mathbf V + \mathbf V = \mathbf 0&lt;/script&gt;, this implies it satisifies closure under addition&lt;/p&gt;

&lt;p&gt;so it is a subspace.&lt;/p&gt;

&lt;h3 id=&quot;example-2&quot;&gt;example 2&lt;/h3&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf S = { \begin{bmatrix}
x_1\\
x_2
\end{bmatrix}
\in \ \mathbf R^2 | x_1 \ge 0 and x_2 \ge 0 }&lt;/script&gt;

&lt;p&gt;is &lt;script type=&quot;math/tex&quot;&gt;\mathbf S&lt;/script&gt; a subspace of &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^2&lt;/script&gt;?&lt;/p&gt;

&lt;p&gt;1:&lt;/p&gt;

&lt;p&gt;because &lt;script type=&quot;math/tex&quot;&gt;x_1, x_2 \ge 0&lt;/script&gt;, so it contains the zero vector.&lt;/p&gt;

&lt;p&gt;2:&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\begin{bmatrix}
a\\
b
\end{bmatrix}
+
\begin{bmatrix}
c\\
d
\end{bmatrix}
=
\begin{bmatrix}
a+c\\
b+d
\end{bmatrix}&lt;/script&gt;

&lt;p&gt;it satisifies the closure of addition&lt;/p&gt;

&lt;p&gt;3: however, if&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;-1
\begin{bmatrix}
a\\
b
\end{bmatrix}
=
\begin{bmatrix}
-a\\
-b
\end{bmatrix}&lt;/script&gt;

&lt;p&gt;This does not satisify the closure of multiplication because the result falls out of the restricted set. 
(it is less than 0)&lt;/p&gt;

&lt;h3 id=&quot;example-3-1&quot;&gt;example 3&lt;/h3&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;let \ \mathbf U = \ span \ (\vec v_1,\vec v_2, \vec v_3)&lt;/script&gt;

&lt;p&gt;Is it subspace of &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^3&lt;/script&gt;?&lt;/p&gt;

&lt;p&gt;1: if&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;(0\vec v_1 +0\vec v_2+ 0\vec v_3 = \vec 0)&lt;/script&gt;

&lt;p&gt;so it contains the zero vector.&lt;/p&gt;

&lt;p&gt;2:&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec X =c_1\vec v_1+c_2\vec v_2+ c_3\vec v_3&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;a\vec X =ac_1\vec v_1+ac_2\vec v_2+ ac_3\vec v_3&lt;/script&gt;

&lt;p&gt;if we let &lt;script type=&quot;math/tex&quot;&gt;ac_i = j_i&lt;/script&gt;&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;a\vec X =j_1\vec v_1+j_2\vec v_2+ j_3\vec v_3&lt;/script&gt;

&lt;p&gt;clear, it is just a linear combination of the 3 vectors and it is in the span of the 3 vectors, therefore it satisifies the closure of multiplication.&lt;/p&gt;

&lt;p&gt;3:&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec Y =d_1\vec v_1+d_2\vec v_2+ d_3\vec v_3&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec X + \vec Y =(c_1+d_1)\vec v_1+(c_2+d_2)\vec v_2+ (c_3+d_3)\vec v_3&lt;/script&gt;

&lt;p&gt;It clearly satisify the closure under addition&lt;/p&gt;

&lt;p&gt;so it is a subspace of &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^3&lt;/script&gt;&lt;/p&gt;

&lt;h2 id=&quot;basis&quot;&gt;Basis&lt;/h2&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf S = 
\left(\begin{bmatrix}
2\\
3
\end{bmatrix}
,
(\begin{bmatrix}
7\\
0
\end{bmatrix}
\right)&lt;/script&gt;

&lt;p&gt;What is the span of $$\mathbf S?&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf S = 
\left(c_1\begin{bmatrix}
2\\
3
\end{bmatrix}
+c_2\begin{bmatrix}
7\\
0
\end{bmatrix}
\right)&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;2c_1+7c_2 = x_1 \\
3c_1 + 0 = x_2 \\
c_1=\frac {x_2}{3} , c_2 = \frac{x_1}{7}-\frac{2}{21}x_2&lt;/script&gt;

&lt;p&gt;is &lt;script type=&quot;math/tex&quot;&gt;\mathbf S&lt;/script&gt; linear independent?&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf S = 
\left(c_1\begin{bmatrix}
2\\
3
\end{bmatrix}
+c_2\begin{bmatrix}
7\\
0
\end{bmatrix} 
\right) =
= \begin{bmatrix}
0\\
0
\end{bmatrix}&lt;/script&gt;

&lt;p&gt;from above&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;c_1=\frac {x_2}{3} , c_2 = \frac{x_1}{7}-\frac{2}{21}x_2 \\
c_1=\frac {0_2}{3} , c_2 = \frac{x_1}{7}-\frac{2}{21}0 \\
c_1 = 0, c_2 = 0&lt;/script&gt;

&lt;p&gt;Since &lt;script type=&quot;math/tex&quot;&gt;\mathbf S \ spans \ \mathbf R^2&lt;/script&gt; and it is linear independent, so &lt;script type=&quot;math/tex&quot;&gt;\mathbf S&lt;/script&gt; is a basis for &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^2&lt;/script&gt;.&lt;/p&gt;

&lt;h3 id=&quot;example-1-1&quot;&gt;example 1&lt;/h3&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf T = 
\left(\begin{bmatrix}
1\\
0
\end{bmatrix}
,
(\begin{bmatrix}
0\\
1
\end{bmatrix}
\right)&lt;/script&gt;

&lt;p&gt;What is the span of &lt;script type=&quot;math/tex&quot;&gt;\mathbf T&lt;/script&gt;?&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf T = 
\left(x_1\begin{bmatrix}
1\\
0
\end{bmatrix}
+x_2\begin{bmatrix}
0\\
1
\end{bmatrix} 
\right) =
= \begin{bmatrix}
x_1\\
x_2
\end{bmatrix}&lt;/script&gt;

&lt;p&gt;from above we know that the span is &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^2&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;Is it linear independent?&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf T = 
\left(x_1\begin{bmatrix}
1\\
0
\end{bmatrix}
+x_2\begin{bmatrix}
0\\
1
\end{bmatrix} 
\right) =
= \begin{bmatrix}
0\\
0
\end{bmatrix}&lt;/script&gt;

&lt;p&gt;to satisify the above, &lt;script type=&quot;math/tex&quot;&gt;x_1,x_2&lt;/script&gt; have to be 0.&lt;/p&gt;

&lt;p&gt;so &lt;script type=&quot;math/tex&quot;&gt;\mathbf T&lt;/script&gt; is a basis.&lt;/p&gt;

&lt;p&gt;In fact, &lt;script type=&quot;math/tex&quot;&gt;\mathbf T&lt;/script&gt; is the unit vector &lt;script type=&quot;math/tex&quot;&gt;\hat i \ and \ \hat j&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;conclusion&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf P {v_1,v_2 \cdots v_n} = Basis \ for \ \mathbf U&lt;/script&gt;

&lt;p&gt;any member of the set &lt;script type=&quot;math/tex&quot;&gt;\mathbf U&lt;/script&gt; is a unique combination of the basis &lt;script type=&quot;math/tex&quot;&gt;\mathbf P&lt;/script&gt;&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec a \in U \vec a = c_1\vec v_1 + c_2\vec v_2 + \cdots c_n\vec v_n&lt;/script&gt;

&lt;p&gt;let’s prove the uniqueness by contraditon&lt;/p&gt;

&lt;p&gt;assume that they are not unique&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec a = c_1\vec v_1 + c_2\vec v_2 + \cdots c_n\vec v_n&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec a = d_1\vec d_1 + d_2\vec v_2 + \cdots d_n\vec v_n&lt;/script&gt;

&lt;p&gt;then if&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec a = c_1\vec v_1 + c_2\vec v_2 + \cdots c_n\vec v_n \\
\vec a = d_1\vec v_1 + d_2\vec v_2 + \cdots d_n\vec v_n \\
0 = (c_1-d_1)\vec v_1 +(c_2-d_2)\vec v_2 + \cdots (c_1-d_n)\vec v_n&lt;/script&gt;

&lt;p&gt;since &lt;script type=&quot;math/tex&quot;&gt;\mathbf P&lt;/script&gt; is the basis of &lt;script type=&quot;math/tex&quot;&gt;\mathbf U&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;so it has to be linear independent, thus &lt;script type=&quot;math/tex&quot;&gt;c_i-d_i = 0&lt;/script&gt;, therefore, &lt;script type=&quot;math/tex&quot;&gt;c_i&lt;/script&gt; is unique.&lt;/p&gt;

&lt;h2 id=&quot;dot-product&quot;&gt;Dot product&lt;/h2&gt;

&lt;h3 id=&quot;definition&quot;&gt;definition&lt;/h3&gt;

&lt;p id=&quot;geo_def&quot;&gt;&lt;/p&gt;
&lt;p&gt;Geometric definition 
&lt;script type=&quot;math/tex&quot;&gt;\vec v\cdot\vec w = \left\|v\right\|\left\|w\right\|cos\theta \quad\text{Where}\quad\theta\quad \text{is the angle between}\quad\vec v \ \text{and} \ \vec w \quad and 0 \le \theta\le\pi&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;Algebraic definition 
&lt;script type=&quot;math/tex&quot;&gt;\vec v\cdot\vec w = v_1w_1+v_2w_2+v_3w_3.&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/linear%20algebra/2015/11/18/proof-linear-algebra/#linear_dependence&quot;&gt;see proof&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;vector-into-components-projection&quot;&gt;vector into components: projection&lt;/h3&gt;

&lt;p&gt;From the figure, we see that &lt;script type=&quot;math/tex&quot;&gt;\vec v&lt;/script&gt; is broken into two components &lt;script type=&quot;math/tex&quot;&gt;\vec v_{parallel} \ \vec v_{prep}&lt;/script&gt; and they are 
perpendicular, respectively, to a given nonzero vector, &lt;script type=&quot;math/tex&quot;&gt;\vec u&lt;/script&gt; Figure from &lt;a href=&quot;http://www.amazon.com/Calculus-Single-Variable-Deborah-Hughes-Hallett/dp/0470089156&quot;&gt;Hughes-Hallett 5e&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;/assets/LinearAlgebra/projection.png&quot; alt=&quot;projection&quot; /&gt;&lt;/p&gt;

&lt;p&gt;To compute &lt;script type=&quot;math/tex&quot;&gt;\left\|\vec v_{parallel}\right\| = \left\|\vec v\right\|cos\theta = \vec v\cdot\vec u \quad (since \ \left\|\vec u\right\| =1)&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;then&lt;script type=&quot;math/tex&quot;&gt;\vec v_{parallel}\text{is a scalar multiple of $\vec u$, and since $\vec u$ is a unit vector}&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;\vec v_{parallel} = (\left\|\vec v\right\|cos\theta)\vec u = (\vec v\cdot\vec u)\vec u.&lt;/script&gt; according to the&lt;/p&gt;
&lt;p&gt;&lt;a href=&quot;#geo_def&quot;&gt;geometric definition&lt;/a&gt;&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec_{prep} = \vec v - \vec v_{parallel}&lt;/script&gt;

</description>
        <pubDate>Sun, 22 Nov 2015 00:00:00 -0600</pubDate>
        <link>http://lanyon.getpoole.com/linear%20algebra/2015/11/22/linear-algebra_study_note/</link>
        <guid isPermaLink="true">http://lanyon.getpoole.com/linear%20algebra/2015/11/22/linear-algebra_study_note/</guid>
        
        <category>vector</category>
        
        <category>linear algebra</category>
        
        
        <category>linear algebra</category>
        
      </item>
    
      <item>
        <title>Proof in vector space</title>
        <description>&lt;ul id=&quot;markdown-toc&quot;&gt;
  &lt;li&gt;&lt;a href=&quot;#prove-that-a-vector-space-has-only-one-zero-vector&quot; id=&quot;markdown-toc-prove-that-a-vector-space-has-only-one-zero-vector&quot;&gt;Prove that a vector space has only one zero vector.&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#proof-of-linear-dependence&quot; id=&quot;markdown-toc-proof-of-linear-dependence&quot;&gt;proof of linear dependence&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;h2 id=&quot;prove-that-a-vector-space-has-only-one-zero-vector&quot;&gt;Prove that a vector space has only one zero vector.&lt;/h2&gt;

&lt;p&gt;(Exercise 4.2, 19.) 
&lt;!--break--&gt;
Solution: Suppose that z1 and z2 are two zero vectors of the vector space.
Since z1 is a zero vector, and z2 another vector, by the third property (page 189) in the definition of a vector space. 
z2 ⊕z1 =z1 ⊕z2 =z2&lt;/p&gt;

&lt;p&gt;Comment: That is, just plug in z1 where you see 0, and z2 where you see u. Similarly, since
z2 is a zero vector, and z1 is another vector, we have:
z1 ⊕z2 =z2 ⊕z1 =z1&lt;/p&gt;

&lt;p&gt;By the two equations above, we have
z1 ⊕ z2 = z1 = z2
Thus z1 = z2. That is, any two zero vectors must be equal, so that the zero vector is unique.&lt;/p&gt;

&lt;ol&gt;
  &lt;li&gt;Prove that a vector u in a vector space has only one negative, -u. (Exercise 4.2, 20.)&lt;/li&gt;
&lt;/ol&gt;

&lt;p&gt;Solution: Suppose that v and w are two additive inverses of u. Since w is an additive inverse&lt;/p&gt;

&lt;p&gt;Add v to both sides.&lt;/p&gt;

&lt;p&gt;v⊕u⊕w = v⊕0 v⊕u⊕w = v
􏰂 􏰁􏰀 􏰃
0
u⊕w=0
(property 3 in vector space defn)
(property 4, since v is an additive inverse) (property 3)
￼￼0⊕w = v w= v
Thus, w = v, so that the additive inverse of u is unique.&lt;/p&gt;

&lt;p id=&quot;linear_dependence&quot;&gt;&lt;/p&gt;

&lt;h2 id=&quot;proof-of-linear-dependence&quot;&gt;proof of linear dependence&lt;/h2&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec v_1 = c_2\vec v_2 + c_3\vec c_3 + \cdots c_n\vec v_n&lt;/script&gt;

&lt;p&gt;Then at least one of the constant is non-zero&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;0 = -1\vec v_1 + c_2\vec c_2 + a_3\vec c_3 + \cdots c_n\vec v_n&lt;/script&gt;

&lt;p&gt;assume c1 is non-zero&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec v_1 + \frac{c_2}{c1}\vec v_2 + \cdots + \frac{c_n}{c_1}\vec v_n = 0&lt;/script&gt;

&lt;p id=&quot;doc_product_loc&quot;&gt;&lt;/p&gt;
&lt;p&gt;Suppose that &lt;script type=&quot;math/tex&quot;&gt;% &lt;![CDATA[
0&lt;\theta&lt;\pi, \ \text{so that the vectors} \ \vec v \ and \ \vec w %]]&gt;&lt;/script&gt;  form a triangle. By the law of Cosines&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\left\|\vec v-\vec w\right\|^2 = \left\|\vec v\right\| + \left\|\vec w\right\| -2\left\|\vec v\right\| cos\theta&lt;/script&gt;

&lt;p&gt;also true for &lt;script type=&quot;math/tex&quot;&gt;\theta = 0 \ and \ \theta = \pi&lt;/script&gt;&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\left\|\vec v\right\|^2 = v_1^2+v_2^2+v_3^2&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\left\|\vec w\right\|^2 = w_1^2+w_2^2+w_3^2&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\left\|\vec v-\vec w\right\|^2 =(v_1-w_1)^2+(v_3-w_3)^2+(v_3-w_3)^2
=v_1^2 -2v_1w_1+w_1^2+v_2^2 - 2v_2w_2 + w_2^2+v_3^2-2v_3w_3+w_3^2&lt;/script&gt;

&lt;p&gt;Substitute into the Law of Cosines&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;-2v_1w_1-2v_2w_2-2v_3w_3=-2\left\|\vec v\right\|\left\|\vec w\right\|cos \theta&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;v_1w_1-v_2w_2-v_3w_3=\left\|\vec v\right\|\left\|\vec w\right\|cos \theta&lt;/script&gt;
</description>
        <pubDate>Wed, 18 Nov 2015 00:00:00 -0600</pubDate>
        <link>http://lanyon.getpoole.com/linear%20algebra/2015/11/18/proof-linear-algebra/</link>
        <guid isPermaLink="true">http://lanyon.getpoole.com/linear%20algebra/2015/11/18/proof-linear-algebra/</guid>
        
        <category>linear algebra</category>
        
        <category>proof</category>
        
        <category>vector space</category>
        
        
        <category>linear algebra</category>
        
      </item>
    
      <item>
        <title>Statistics for Genomic Data Science</title>
        <description>&lt;p&gt;Statistics for Genomic Data Science&lt;/p&gt;

&lt;p&gt;week 1&lt;/p&gt;

&lt;p&gt;week 2&lt;/p&gt;

&lt;p&gt;Asian Institute in Statistical Genetics and Genomics
&lt;a href=&quot;http://www.biostat.jhsph.edu/~iruczins/teaching/kogo/&quot;&gt;Statistical Genomics&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;linear-models-with-categorical-covariateshttpsdocsgooglecompresentationd1pqjeviktzvmmsmsrdn30urxhgmptq-b0ucgoh7qeekoeditslideidgc6c125a130233&quot;&gt;&lt;a href=&quot;https://docs.google.com/presentation/d/1pqjeVIkTZVMmsmSrDn30UrxhgMPTQ-b0uCgoh7QEeko/edit#slide=id.gc6c125a13_0_233&quot;&gt;Linear models with Categorical Covariates&lt;/a&gt;&lt;/h3&gt;

&lt;p&gt;Thomas Lumley &amp;amp; Ken Rice
&lt;a href=&quot;http://faculty.washington.edu/kenrice/teaching.html&quot;&gt;Ken Rice&lt;/a&gt;
&lt;a href=&quot;http://faculty.washington.edu/kenrice/sisg/sisg-lie11-04.pdf&quot;&gt;slides&lt;/a&gt; in pdf format
&lt;a href=&quot;http://faculty.washington.edu/kenrice/sisg/session4lie11.R&quot;&gt;R code&lt;/a&gt; of the slides&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.statsci.org/smyth/pubs/limma-biocbook-reprint.pdf&quot;&gt;Limma: Linear Models for Microarray Data&lt;/a&gt;&lt;/p&gt;

</description>
        <pubDate>Sat, 14 Nov 2015 00:00:00 -0600</pubDate>
        <link>http://lanyon.getpoole.com/genomic%20data%20science/2015/11/14/Genomic-Data-Science-JH/</link>
        <guid isPermaLink="true">http://lanyon.getpoole.com/genomic%20data%20science/2015/11/14/Genomic-Data-Science-JH/</guid>
        
        <category>Coursera</category>
        
        <category>statistics</category>
        
        <category>Johns Hopkin</category>
        
        <category>Jeff Leek</category>
        
        <category>Genomic</category>
        
        <category>Data Science</category>
        
        
        <category>genomic data science</category>
        
      </item>
    
      <item>
        <title>correlation study</title>
        <description>&lt;p&gt;&lt;a href=&quot;https://cran.r-project.org/web/packages/corrplot/vignettes/corrplot-intro.html&quot;&gt;An Introduction to corrplot package&lt;/a&gt;&lt;/p&gt;
</description>
        <pubDate>Fri, 30 Oct 2015 00:00:00 -0500</pubDate>
        <link>http://lanyon.getpoole.com/statistics/2015/10/30/correlation-study/</link>
        <guid isPermaLink="true">http://lanyon.getpoole.com/statistics/2015/10/30/correlation-study/</guid>
        
        <category>R</category>
        
        <category>correlation</category>
        
        <category>corrplot</category>
        
        
        <category>statistics</category>
        
      </item>
    
      <item>
        <title>Ipython and Jupyter study</title>
        <description>&lt;p&gt;video resource&lt;/p&gt;

&lt;p&gt;IPython &amp;amp; Jupyter in depth: high productivity interactive and parallel python - PyCon 2015&lt;/p&gt;

&lt;iframe width=&quot;560&quot; height=&quot;315&quot; src=&quot;https://www.youtube.com/embed/05fA_DXgW-Y&quot; frameborder=&quot;0&quot; allowfullscreen=&quot;&quot;&gt;&lt;/iframe&gt;
</description>
        <pubDate>Fri, 30 Oct 2015 00:00:00 -0500</pubDate>
        <link>http://lanyon.getpoole.com/python/2015/10/30/Ipython-Jupyter-study/</link>
        <guid isPermaLink="true">http://lanyon.getpoole.com/python/2015/10/30/Ipython-Jupyter-study/</guid>
        
        <category>Ipython</category>
        
        <category>Jupyter</category>
        
        <category>python</category>
        
        <category>notebook</category>
        
        
        <category>python</category>
        
      </item>
    
      <item>
        <title>exam2 review note from textbooks and others</title>
        <description>&lt;h2 id=&quot;wbc-and-lymphoid&quot;&gt;WBC and Lymphoid&lt;/h2&gt;

&lt;h3 id=&quot;keywords&quot;&gt;keywords&lt;/h3&gt;
&lt;!--break--&gt;
&lt;p&gt;&lt;a href=&quot;https://en.wikipedia.org/wiki/Emperipolesis#/media/File:Emperipolesis_-_very_high_mag.jpg&quot;&gt;emperipolesis&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;an intact cell within the cytoplasm of another cell&lt;/p&gt;

&lt;h2 id=&quot;note-from-books&quot;&gt;note from books&lt;/h2&gt;

&lt;h3 id=&quot;acute-leukemias-in-general&quot;&gt;Acute Leukemias in general&lt;/h3&gt;

&lt;p&gt;oncogenic tyrosine kinases activate RAS and its two downstream signaling arms, the PI3K/AKT and MAPK pathways&lt;/p&gt;

&lt;p&gt;B-ALL and CML -&amp;gt; BCR-ABL fusion gene (9,22) translocation, philiadelphia chromosome.&lt;/p&gt;

&lt;p&gt;some T-ALLs -&amp;gt; NUP214-ABL (similar to BCR-ABL)&lt;/p&gt;

&lt;p&gt;Acute leukemias have the following characteristics:&lt;/p&gt;

&lt;p&gt;a lack of CD7 expression could insinuate mycosis fungoides (MF) or Sezary syndrome (SS).&lt;/p&gt;

&lt;h4 id=&quot;laboratory-findings-in-acute-leukemias&quot;&gt;Laboratory Findings in Acute Leukemias&lt;/h4&gt;

&lt;p&gt;(WBC count) variable; maybe &amp;gt; 100,000 cells/μL, in 50% of patient, &amp;lt; 10,000 cells/μL.&lt;/p&gt;

&lt;p&gt;Anemia is almost always present&lt;/p&gt;

&lt;p&gt;platelet count 00,000/μL&lt;/p&gt;

&lt;p&gt;Neutropenia&lt;/p&gt;

&lt;h4 id=&quot;all-immunophenotypic-features&quot;&gt;ALL Immunophenotypic Features&lt;/h4&gt;

&lt;p&gt;Terminal deoxynucleotidyl transferase (TdT) -&amp;gt; pre-B and pre-T cells&lt;/p&gt;

&lt;p&gt;Further subtyping of ALL -&amp;gt; lineage-specific markers, such as CD19 (B cell) and CD3 (T cell).&lt;/p&gt;

&lt;h4 id=&quot;b-lymphoblastic-leukemialymphoma-immunophenotype&quot;&gt;B lymphoblastic leukemia/lymphoma: Immunophenotype&lt;/h4&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;CD19 – pan-B-cell marker&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD10  - Common Acute Lymphoblastic Leukemia Antigen (CALLA), most cases&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD34 – stem cell marker, most cases&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;TdT – nearly all cases&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Cytoplasmic IgM heavy chain (μ chain)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Only in the more mature “late pre-B” cases&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Otherwise, ALL are negative for Ig&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Distinguishes ALL from mature B-cell leukemia/lymphoma&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h4 id=&quot;t-lymphoblastic-leukemialymphoma-immunophenotype&quot;&gt;T lymphoblastic leukemia/lymphoma: Immunophenotype&lt;/h4&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;TdT – many cases&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Most T-cell antigens positive: CD1a, CD2, cytoplasmic CD3, CD5, and CD7&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD1a - T-cell markers often negative: surface CD3, CD4 and CD8&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD4 and CD8 often negative in more immature forms&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD4 and CD8 often positive in more mature forms&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h4 id=&quot;b-lymphoblastic-leukemialymphoma-genetics&quot;&gt;B lymphoblastic leukemia/lymphoma: genetics&lt;/h4&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Abnormality&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Frequency&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Prognosis&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;t(v;11q23), MLL, early precursor&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;2-3%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;&lt;strong&gt;unfavorable&lt;/strong&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;t(9;22), Ph1, BCR-ABL1&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;3-4%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;&lt;strong&gt;unfavorable&lt;/strong&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(25% adults)&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;t(12;21) TEL/AML1&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;16-19%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;favorable&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Hyperdiploid &amp;gt; 50&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;20-25%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;favorable&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Hypodiploid&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;5%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;&lt;strong&gt;unfavorable&lt;/strong&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Antigen  Designation&lt;/th&gt;
      &lt;th style=&quot;text-align: left&quot;&gt;Normal Cellular Distribution&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Primarily T-Cell Associated&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD1&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Thymocytes and Langerhans cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD3&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Thymocytes, mature T cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD4&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Helper T cells, subset of thymocytes&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD5&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;T cells and a small subset of B cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD8&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Cytotoxic T cells, subset of thymocytes, and some NK cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Primarily B-Cell Associated&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;BCL6&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;a transcription factor required for the generation of germinal center B cells.&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD10&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Pre-B cells and germinal-center B cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD19&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Pre-B cells and mature B cells but not plasma cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD20&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Pre-B cells after C19 and mature B cells but not plasma  cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD21&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;EBV receptor; mature B cells and follicular dendritic cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD23&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Activated mature B cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD79a&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Marrow pre-B cells and mature B cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Primarily Monocyte or Macrophage Associated&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD11c&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Granulocytes, monocytes, and macrophages; also  expressed by hairy cell leukemias&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD13&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Immature and mature monocytes and granulocytes&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD14&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Monocytes&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD15&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Granulocytes; Reed-Sternberg cells and variants&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD33&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Myeloid progenitors and monocytes&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD64&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Mature myeloid cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Primarily NK-Cell Associated&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD16&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;NK cells and granulocytes&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD56&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;NK cells and a subset of T cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Primarily Stem Cell and Progenitor Cell Associated&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD34&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Pluripotent hematopoietic stem cells and progenitor cells  of many lineages&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Activation Markers&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD30&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Activated B cells, T cells, and monocytes; Reed-Sternberg  cells and variants&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Present on All Leukocytes&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD45&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;All leukocytes; also known as leukocyte common antigen  (LCA)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Diagnosis&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Cell of Origin&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Genotype&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Salient Clinical Features&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Neoplasms of Immature B and T Cells&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;B-cell acute lymphoblastic  leukemia/lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Bone marrow precursor  B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Diverse chromosomal translocations;  t(12;21) involving RUNX1 and ETV6  present in 25%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Predominantly children; symptoms relating to marrow  replacement and pancytopenia; aggressive&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;T-cell acute lymphoblastic  leukemia/lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Precursor T cell (often  of thymic origin)&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Diverse chromosomal translocations,  NOTCH1 mutations (50%-70%)&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Predominantly adolescent males; thymic masses and  variable bone marrow involvement; aggressive&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Neoplasms of Mature B Cells&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Burkitt lymphoma*&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Germinal-center B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Translocations involving MYC and lg loci,  usually t(8;14); subset EBV-associated&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Adolescents or young adults with extranodal masses;  uncommonly presents as “leukemia”; aggressive&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Diffuse large B-cell  lymphoma†&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Germinal-center or  postgerminal center  B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Diverse chromosomal rearrangements,  most often of BCL6 (30%), BCL2 (10%),  or MYC (5%)&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;All ages, but most common in older adults; often appears  as a rapidly growing mass; 30% extranodal; aggressive&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Extranodal marginal zone  lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Memory B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;t(11;18), t(1;14), and t(14;18) creating  MALT1-IAP2, BCL10-IgH, and  MALT1-IgH fusion genes, respectively&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Arises at extranodal sites in adults with chronic  inflammatory diseases; may remain localized; indolent&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Follicular lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Germinal-center B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;t(14;18) creating BCL2-IgH fusion gene&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Older adults with generalized lymphadenopathy and  marrow involvement; indolent&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Hairy cell leukemia&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Memory B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Activating BRAF mutations&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Older males with pancytopenia and splenomegaly; indolent&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Mantle cell lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Naive B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;t(11;14) creating CyclinD1-IgH fusion gene&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Older males with disseminated disease; moderately  aggressive&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Multiple myeloma/solitary  plasmacytoma†&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Post-germinal-center  bone marrow homing  plasma cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Diverse rearrangements involving IgH; 13q  deletions&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Myeloma: older adults with lytic bone lesions, pathologic  fractures, hypercalcemia, and renal failure; moderately  aggressive&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Plasmacytoma: isolated plasma cell masses in bone or  soft tissue; indolent&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Small lymphocytic  lymphoma/chronic  lymphocytic leukemia&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Naive B cell or memory  B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Trisomy 12, deletions of 11q, 13q, and  17p&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Older adults with bone marrow, lymph node, spleen, and  liver disease; autoimmune hemolysis and  thrombocytopenia in a minority; indolent&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Neoplasms of Mature T Cells or NK Cells&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Adult T-cell leukemia/ lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Helper T cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;HTLV-1 provirus present in tumor cells&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Adults with cutaneous lesions, marrow involvement, and  hypercalcemia; occurs mainly in Japan, West Africa,  and the Caribbean; aggressive&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Peripheral T-cell lymphoma,  unspecified&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Helper or cytotoxic   T cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;No specific chromosomal abnormality&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Mainly older adults; usually presents with  lymphadenopathy; aggressive&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Anaplastic large-cell  lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Cytotoxic T cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Rearrangements of ALK (anaplastic large  cell lymphoma kinase) in a subset&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Children and young adults, usually with lymph node and  soft-tissue disease; aggressive&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Extranodal NK/T-cell  lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;NK-cell (common) or  cytotoxic T cell (rare)&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;EBV-associated; no specific chromosomal  abnormality&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Adults with destructive extranodal masses, most  commonly sinonasal; aggressive&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Mycosis fungoides/Sézary  syndrome&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Helper T cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;No specific chromosomal abnormality&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Adult patients with cutaneous patches, plaques, nodules,  or generalized erythema; indolent&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Large granular lymphocytic  leukemia&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Two types: cytotoxic T  cell and NK cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Point mutations in STAT3&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Adult patients with splenomegaly, neutropenia, and  anemia, sometimes, accompanied by autoimmune  disease&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;*Most common tumors in children&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;†Most common tumors in adults.&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;EBV, Epstein-Barr virus; HIV, human immunodeficiency virus; Ig, immunoglobulin; NK, natural killer.&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;Immunophenotype of chronic B-cell neoplasms&lt;/p&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;neoplasm&lt;/td&gt;
      &lt;td&gt;CD19CD20&lt;/td&gt;
      &lt;td&gt;CD5&lt;/td&gt;
      &lt;td&gt;CD10&lt;/td&gt;
      &lt;td&gt;CD23&lt;/td&gt;
      &lt;td&gt;sIg&lt;/td&gt;
      &lt;td&gt;CD103&lt;/td&gt;
      &lt;td&gt;Cyclin D1&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;:—:&lt;/td&gt;
      &lt;td&gt;:—:&lt;/td&gt;
      &lt;td&gt;:—:&lt;/td&gt;
      &lt;td&gt;:—:&lt;/td&gt;
      &lt;td&gt;:—:&lt;/td&gt;
      &lt;td&gt;:—:&lt;/td&gt;
      &lt;td&gt;:—:&lt;/td&gt;
      &lt;td&gt;:—:&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;CLL/SLL&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-/+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;MCL&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;FL&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;++&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;MZL&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;+++&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;HCL&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;+++&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;+/-&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h4 id=&quot;leukocyte-alkaline-phosphatase&quot;&gt;Leukocyte alkaline phosphatase&lt;/h4&gt;

&lt;p&gt;Leukocyte alkaline phosphatase (LAP) is found within mature white blood cells. White blood cell levels of LAP can help in the diagnosis of certain conditions.&lt;/p&gt;

&lt;p&gt;Higher levels are seen in polycythemia vera (PV), essential thrombocytosis (ET), primary myelofibrosis (PM), and the leukemoid reaction.
Lower levels are found in chronic myelogenous leukemia(CML), paroxysmal nocturnal hemoglobinuria (PNH) and acute myelogenous leukaemia (AML).&lt;/p&gt;

&lt;h4 id=&quot;cllsll&quot;&gt;CLL/SLL&lt;/h4&gt;

&lt;p&gt;circulating  nucleated  red  cells  could  stem  from  premature  release  of  progenitors  in  the  face  of  severe anemia&lt;/p&gt;

&lt;p&gt;The most promising new therapy is BTK inhibitors, described earlier.&lt;/p&gt;

&lt;h3 id=&quot;blood-count-note&quot;&gt;blood count note&lt;/h3&gt;

&lt;p&gt;observing CBC and blood count&lt;/p&gt;

&lt;p&gt;platlet count -&amp;gt; thrombocytopenia&lt;/p&gt;

&lt;p&gt;Normal bone marrow -&amp;gt; exclude acute lymphoid or myeloid leukemia&lt;/p&gt;

&lt;p&gt;reduction in RBCs, WBCs, and platelet production -&amp;gt; aplastic anemia&lt;/p&gt;

&lt;p&gt;band neutrophil -&amp;gt; left shift -&amp;gt; inflammatory condition&lt;/p&gt;

</description>
        <pubDate>Tue, 13 Oct 2015 00:00:00 -0500</pubDate>
        <link>http://lanyon.getpoole.com/pathology/2015/10/13/exam2-review-textbook/</link>
        <guid isPermaLink="true">http://lanyon.getpoole.com/pathology/2015/10/13/exam2-review-textbook/</guid>
        
        <category>pathology</category>
        
        <category>diseases</category>
        
        <category>textbook</category>
        
        <category>Lab Med</category>
        
        
        <category>pathology</category>
        
      </item>
    
      <item>
        <title>Hemodynamics Supplimentary Material</title>
        <description>
&lt;hr /&gt;
&lt;p&gt;layout: post
comments: True
title: Bleeding and Thrombotic Disorders
category: Pathology
tags: [pathology, diseases, textbook, Lab Med]
—&lt;/p&gt;

&lt;h2 id=&quot;hemodynamics-and-bleeding-disorders&quot;&gt;Hemodynamics and bleeding disorders&lt;/h2&gt;

&lt;p&gt;TABLE 2.-Causes of Pleural Effusions&lt;/p&gt;

&lt;h3 id=&quot;transudates&quot;&gt;Transudates&lt;/h3&gt;
&lt;!--break--&gt;
&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Congestive heart failure&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Cirrhosis with ascites&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Nephrotic syndrome Hypoalbuminemia&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Peritoneal dialysis Atelectasis,acute&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Superior vena cava obstruction Subclavian catheter misplacement Early mediastinal malignancy&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;exudates&quot;&gt;Exudates&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Parapneumonic effusion (bacterial pneumonia) Pulmonary infarction&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Malignancy (direct pleural involvement, late mediasti-&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;nalinvolvement)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Viral disease&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Connective tissue disease (lupus, rheumatoid, mixed) Tuberculosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Fungal disease&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Parasitic disease (Entamoeba histolytica, Paragonimus&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;westermani)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Gastrpintestinal disease (pancreatitis, esophageal rup-&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;ture, subphrenic abscess)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Drug reaction (nitrofurantoin, methysergide) Asbestos&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Meigs’ syndrome&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Postmyocardial infarction and postcardiac surgical&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;operation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Trapped lung Lymphatic abnormality Uremic pleurisy Atelectasis,chronic Chylothorax Sarcoidosis&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;
</description>
        <pubDate>Mon, 12 Oct 2015 00:00:00 -0500</pubDate>
        <link>http://lanyon.getpoole.com/2015/10/12/hemodynamics-supplimentary-material/</link>
        <guid isPermaLink="true">http://lanyon.getpoole.com/2015/10/12/hemodynamics-supplimentary-material/</guid>
        
        
      </item>
    
      <item>
        <title>Assignment 4 Creating graphs for your data</title>
        <description>&lt;p&gt;to download my python code &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/TempDataScienceCourse/Assignment%204/Assignment%204.py&quot;&gt;click here&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;to download the dataset &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/TempDataScienceCourse/Assignment%204/gapminder.csv&quot;&gt;click here&lt;/a&gt;&lt;/p&gt;

&lt;!--break--&gt;

&lt;p&gt;to download the ipython notebook file &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/TempDataScienceCourse/Assignment%204/Assignment%204.ipynb.json&quot;&gt;click here&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;To visit my assignment result, please &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/TempDataScienceCourse/Assignment%204/Assignment%204.html&quot;&gt;click here&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;to visit my previous assignments for reference, &lt;a href=&quot;http://jizongl.github.io/DataManagement/&quot;&gt;please click here&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;instructions&quot;&gt;instructions&lt;/h3&gt;

&lt;p&gt;Continue with the program you’ve successfully run.&lt;/p&gt;

&lt;p&gt;STEP 1: Create graphs of your variables one at a time (univariate graphs).&lt;/p&gt;

&lt;p&gt;Examine both their center and spread.&lt;/p&gt;

&lt;p&gt;STEP 2: Create a graph showing the association between your explanatory and response variables (bivariate graph).&lt;/p&gt;

&lt;p&gt;Your output should be interpretable (i.e. organized and labeled).&lt;/p&gt;

&lt;h3 id=&quot;review-criteria-less&quot;&gt;Review Criteria less&lt;/h3&gt;

&lt;p&gt;Your assessment will be based on the evidence you provide that you have completed all of the steps. When relevant, gradients in the scoring will be available to reward clarity (for example, you will get one point for submitting graphs that do not accurately represent your data, but two points if the data is accurately represented). In all cases, consider that the peer assessing your work is likely not an expert in the field you are analyzing. You will be assessed equally on your description of your frequency distributions.&lt;/p&gt;

&lt;p&gt;Specific rubric items, and their point values, are as follows:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Was a univariate graph created for each of the selected variables? (2 points)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Was a bivariate graph created for the selected variables? (2 points)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Did the summary describe what the graphs revealed in terms of the individual&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;variables and the relationship between them? (2 points)&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

</description>
        <pubDate>Sun, 11 Oct 2015 00:00:00 -0500</pubDate>
        <link>http://lanyon.getpoole.com/data%20science/2015/10/11/assignment4-creating-graph/</link>
        <guid isPermaLink="true">http://lanyon.getpoole.com/data%20science/2015/10/11/assignment4-creating-graph/</guid>
        
        <category>correlation</category>
        
        <category>data</category>
        
        <category>assignment</category>
        
        
        <category>data science</category>
        
      </item>
    
      <item>
        <title>Coagulation Small Group</title>
        <description>&lt;p&gt;This post is written for the small group presentation on WBC, which is from the pathology course I take at UMMC&lt;/p&gt;

&lt;!--break--&gt;

&lt;ul id=&quot;markdown-toc&quot;&gt;
  &lt;li&gt;&lt;a href=&quot;#case-1&quot; id=&quot;markdown-toc-case-1&quot;&gt;Case 1&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#background-info&quot; id=&quot;markdown-toc-background-info&quot;&gt;background info&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#for-each-of-the-following-patient-signs-give-a-brief-description-of-possible-etiologies&quot; id=&quot;markdown-toc-for-each-of-the-following-patient-signs-give-a-brief-description-of-possible-etiologies&quot;&gt;1. For each of the following patient signs, give a brief description of possible etiologies:&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-coagulation-laboratory-tests-would-you-order-and-why&quot; id=&quot;markdown-toc-what-coagulation-laboratory-tests-would-you-order-and-why&quot;&gt;2. What coagulation laboratory tests would you order and why?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-is-your-interpretation-of-the-complete-blood-count-next-slide&quot; id=&quot;markdown-toc-what-is-your-interpretation-of-the-complete-blood-count-next-slide&quot;&gt;3. What is your interpretation of the complete blood count? (next slide)&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#cbc-count&quot; id=&quot;markdown-toc-cbc-count&quot;&gt;CBC count&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#wbc-differential&quot; id=&quot;markdown-toc-wbc-differential&quot;&gt;WBC differential&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-is-your-interpretation-of-the-following-coagulation-tests-what-do-these-results-rule-in-and-rule-out&quot; id=&quot;markdown-toc-what-is-your-interpretation-of-the-following-coagulation-tests-what-do-these-results-rule-in-and-rule-out&quot;&gt;￼4.  What is your interpretation of the following coagulation tests? What do these results rule-in and rule-out?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#based-on-these-initial-findings-mixing-studies-and-certain-factor-levels-next-question-are-performed-what-is-a-mixing-study-and-how-is-it-performed-what-information-does-a-mixing-study-provide-interpret-the-following-mixing-study-information&quot; id=&quot;markdown-toc-based-on-these-initial-findings-mixing-studies-and-certain-factor-levels-next-question-are-performed-what-is-a-mixing-study-and-how-is-it-performed-what-information-does-a-mixing-study-provide-interpret-the-following-mixing-study-information&quot;&gt;￼5. Based on these initial findings, mixing studies and certain factor levels (next question) are performed. What is a mixing study and how is it performed? What information does a mixing study provide? Interpret the following mixing study information:&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#how-would-you-correct-this-coagulation-problem&quot; id=&quot;markdown-toc-how-would-you-correct-this-coagulation-problem&quot;&gt;7. How would you correct this coagulation problem?&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#case-2&quot; id=&quot;markdown-toc-case-2&quot;&gt;Case 2&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#background-information&quot; id=&quot;markdown-toc-background-information&quot;&gt;background information&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-is-your-interpretation-of-the-complete-blood-count-next-slide-1&quot; id=&quot;markdown-toc-what-is-your-interpretation-of-the-complete-blood-count-next-slide-1&quot;&gt;8. What is your interpretation of the complete blood count (next slide)?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#cbc-count-1&quot; id=&quot;markdown-toc-cbc-count-1&quot;&gt;CBC count&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#wbc-differential-count&quot; id=&quot;markdown-toc-wbc-differential-count&quot;&gt;WBC differential count&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-coagulation-tests-would-you-order-and-why-look-at-the-test-results-what-is-your-interpretation-of-these-coagulation-tests-what-do-the-pfa-100-results-indicate&quot; id=&quot;markdown-toc-what-coagulation-tests-would-you-order-and-why-look-at-the-test-results-what-is-your-interpretation-of-these-coagulation-tests-what-do-the-pfa-100-results-indicate&quot;&gt;9. What coagulation tests would you order and why? Look at the test results. What is your interpretation of these coagulation tests? What do the PFA-100 results indicate?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#based-on-the-clinical-presentation-family-history-and-preliminary-laboratory-results-generate-a-differential-diagnosis-what-is-the-apparent-mode-of-inheritance&quot; id=&quot;markdown-toc-based-on-the-clinical-presentation-family-history-and-preliminary-laboratory-results-generate-a-differential-diagnosis-what-is-the-apparent-mode-of-inheritance&quot;&gt;10. Based on the clinical presentation, family history, and preliminary laboratory results, generate a differential diagnosis. What is the apparent mode of inheritance?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#a-mixing-study-is-performed-what-information-do-you-glean-from-the-results-do-you-have-a-working-diagnosis-how-do-you-explain-the-factor-viii-level&quot; id=&quot;markdown-toc-a-mixing-study-is-performed-what-information-do-you-glean-from-the-results-do-you-have-a-working-diagnosis-how-do-you-explain-the-factor-viii-level&quot;&gt;11. A mixing study is performed. What information do you glean from the results. Do you have a working diagnosis? How do you explain the factor VIII level?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#von-willebrand-disease-manifests-in-several-different-types-discuss-the-three-main-types-and-decide-what-type-of-von-willebrand-disease-this-patient-has&quot; id=&quot;markdown-toc-von-willebrand-disease-manifests-in-several-different-types-discuss-the-three-main-types-and-decide-what-type-of-von-willebrand-disease-this-patient-has&quot;&gt;13. Von Willebrand disease manifests in several different types. Discuss the three main types and decide what type of von Willebrand disease this patient has.&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#how-would-you-manage-this-patients-current-excessive-bleeding-what-choices-are-available-if-surgery-is-required-in-the-future&quot; id=&quot;markdown-toc-how-would-you-manage-this-patients-current-excessive-bleeding-what-choices-are-available-if-surgery-is-required-in-the-future&quot;&gt;15. How would you manage this patient’s current excessive bleeding? What choices are available if surgery is required in the future?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#as-this-young-girl-reaches-the-age-of-60-her-bruising-may-decrease-why&quot; id=&quot;markdown-toc-as-this-young-girl-reaches-the-age-of-60-her-bruising-may-decrease-why&quot;&gt;16. As this young girl reaches the age of 60 her bruising may decrease. Why?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#why-is-the-blood-type-important-in-assessing-a-patient-for-von-willebrand-disease&quot; id=&quot;markdown-toc-why-is-the-blood-type-important-in-assessing-a-patient-for-von-willebrand-disease&quot;&gt;17. Why is the blood type important in assessing a patient for von Willebrand disease?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#briefly-describe-the-subtypes-of-type-2-von-willebrand-disease&quot; id=&quot;markdown-toc-briefly-describe-the-subtypes-of-type-2-von-willebrand-disease&quot;&gt;18.  Briefly describe the subtypes of type 2 von Willebrand disease.&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-is-platelet-type-or-pseudo-vwd&quot; id=&quot;markdown-toc-what-is-platelet-type-or-pseudo-vwd&quot;&gt;19.  What is “platelet type” or “pseudo –vWD”?&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h2 id=&quot;case-1&quot;&gt;Case 1&lt;/h2&gt;

&lt;h3 id=&quot;background-info&quot;&gt;background info&lt;/h3&gt;

&lt;p&gt;An 89 year-old man is admitted to the hospital from a local nursing home with generalized weakness, nausea, vomiting, fever, mild hypertension, and right lower lobe crepitant rales. Additional findings include a pale, cachexic, edentulous, and extremely agitated elderly man who is mildly disoriented to time and place. Examination of the skin reveals numerous small bruises and ecchymoses on arms, forearms, thighs, and the dorsal aspect of both hands. The bruises are of different sizes and various ages. The larger bruises are the more recent bruises and are painful. Blood is noted to extravasate at the phlebotomy sites and bright red blood is noted peri-rectally. The chest x-ray reveals right, lower lobe pneumonia, and the EKG is normal.&lt;/p&gt;

&lt;p&gt;Family History: There is no family history of bleeding problems or bleeding disorders.&lt;/p&gt;

&lt;h3 id=&quot;for-each-of-the-following-patient-signs-give-a-brief-description-of-possible-etiologies&quot;&gt;1. For each of the following patient signs, give a brief description of possible etiologies:&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Bruising&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Ecchymoses&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Extravasation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Rectal Bleeding&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;what-coagulation-laboratory-tests-would-you-order-and-why&quot;&gt;2. What coagulation laboratory tests would you order and why?&lt;/h3&gt;

&lt;h3 id=&quot;what-is-your-interpretation-of-the-complete-blood-count-next-slide&quot;&gt;3. What is your interpretation of the complete blood count? (next slide)&lt;/h3&gt;

&lt;h3 id=&quot;cbc-count&quot;&gt;CBC count&lt;/h3&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;WBC:&lt;/td&gt;
      &lt;td&gt;15,000/mm3&lt;/td&gt;
      &lt;td&gt;(3.0-10.0X103)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Hgb:&lt;/td&gt;
      &lt;td&gt;10.1 mg/dl&lt;/td&gt;
      &lt;td&gt;(12.0-14.0)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Hct:&lt;/td&gt;
      &lt;td&gt;30.5%&lt;/td&gt;
      &lt;td&gt;(39.0-45.0)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;RBC:&lt;/td&gt;
      &lt;td&gt;2.90 m/mm3&lt;/td&gt;
      &lt;td&gt;(4.5-5.9)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;MCV:&lt;/td&gt;
      &lt;td&gt;89 fl&lt;/td&gt;
      &lt;td&gt;(85-99)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;MCH:&lt;/td&gt;
      &lt;td&gt;28 pg&lt;/td&gt;
      &lt;td&gt;(26-34)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;MCHC:&lt;/td&gt;
      &lt;td&gt;34%&lt;/td&gt;
      &lt;td&gt;(31-37)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;RDW:&lt;/td&gt;
      &lt;td&gt;13.0&lt;/td&gt;
      &lt;td&gt;(11.5-14.5)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Platelet Count:&lt;/td&gt;
      &lt;td&gt;200,000/mm3&lt;/td&gt;
      &lt;td&gt;(170-500,000/mm3)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h3 id=&quot;wbc-differential&quot;&gt;WBC differential&lt;/h3&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;Neutrophils&lt;/td&gt;
      &lt;td&gt;60%&lt;/td&gt;
      &lt;td&gt;(44-65)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Bands&lt;/td&gt;
      &lt;td&gt;25%&lt;/td&gt;
      &lt;td&gt;(0-10)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Eosinophils&lt;/td&gt;
      &lt;td&gt;2%&lt;/td&gt;
      &lt;td&gt;(0-9)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Basophils&lt;/td&gt;
      &lt;td&gt;1%&lt;/td&gt;
      &lt;td&gt;(0-4)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Monocytes&lt;/td&gt;
      &lt;td&gt;2%&lt;/td&gt;
      &lt;td&gt;(1-10)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Lymphocytes&lt;/td&gt;
      &lt;td&gt;10%&lt;/td&gt;
      &lt;td&gt;(25-46)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h3 id=&quot;what-is-your-interpretation-of-the-following-coagulation-tests-what-do-these-results-rule-in-and-rule-out&quot;&gt;￼4.  What is your interpretation of the following coagulation tests? What do these results rule-in and rule-out?&lt;/h3&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;Prothrombin time: 21.4 sec&lt;/td&gt;
      &lt;td&gt;(10.5-13.5 sec)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Partial thromboplastin time: 42 sec&lt;/td&gt;
      &lt;td&gt;(25.0-36.0 sec)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Fibrinogen: 310 mg/dl&lt;/td&gt;
      &lt;td&gt;(150-500 mg/dl)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;PFA-100:&lt;/p&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;ADP=110 sec closure&lt;/td&gt;
      &lt;td&gt;(70-120 sec closure)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Epinephrine=98 sec closure&lt;/td&gt;
      &lt;td&gt;(89-189 sec closure)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h3 id=&quot;based-on-these-initial-findings-mixing-studies-and-certain-factor-levels-next-question-are-performed-what-is-a-mixing-study-and-how-is-it-performed-what-information-does-a-mixing-study-provide-interpret-the-following-mixing-study-information&quot;&gt;￼5. Based on these initial findings, mixing studies and certain factor levels (next question) are performed. What is a mixing study and how is it performed? What information does a mixing study provide? Interpret the following mixing study information:&lt;/h3&gt;

&lt;p&gt;Mixing Study with PT:&lt;/p&gt;

&lt;p&gt;| :—: | :—: |
|Dilutions |   Results |
|1:1, 4:1  |  11, 12 seconds |
￼￼
### 6.  Interpret these factor levels. What factors are vitamin K dependent? (hint). What is the diagnosis?&lt;/p&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;Factor&lt;/td&gt;
      &lt;td&gt;VII 20%&lt;/td&gt;
      &lt;td&gt;(50-150%)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Factor&lt;/td&gt;
      &lt;td&gt;V 110%&lt;/td&gt;
      &lt;td&gt;(50-150%)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h3 id=&quot;how-would-you-correct-this-coagulation-problem&quot;&gt;7. How would you correct this coagulation problem?&lt;/h3&gt;

&lt;h2 id=&quot;case-2&quot;&gt;Case 2&lt;/h2&gt;

&lt;h3 id=&quot;background-information&quot;&gt;background information&lt;/h3&gt;

&lt;p&gt;A pale but pleasant twelve year-old seventh grader began menses 14 months ago, and has had severe menorrhagia. She has had frequent nosebleeds since the age of four. An endocrine work-up is negative for anovulatory cycles. A careful history reveals her older sister, mother, and maternal aunt had similar menorrhagia. Her older brother and maternal uncle bruise easily and have frequent nosebleeds. All the members of her family are blood type 0 positive.&lt;/p&gt;

&lt;h3 id=&quot;what-is-your-interpretation-of-the-complete-blood-count-next-slide-1&quot;&gt;8. What is your interpretation of the complete blood count (next slide)?&lt;/h3&gt;

&lt;h3 id=&quot;cbc-count-1&quot;&gt;CBC count&lt;/h3&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;WBC:&lt;/td&gt;
      &lt;td&gt;5400/mm3&lt;/td&gt;
      &lt;td&gt;(3.0-10.0X103)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Hgb:&lt;/td&gt;
      &lt;td&gt;10.1 mg/dl&lt;/td&gt;
      &lt;td&gt;(12.0-14.0)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Hct:&lt;/td&gt;
      &lt;td&gt;29.5%&lt;/td&gt;
      &lt;td&gt;(39.0-45.0)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;RBC:&lt;/td&gt;
      &lt;td&gt;2.89 m/mm3&lt;/td&gt;
      &lt;td&gt;(4.5-5.9)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;MCV:&lt;/td&gt;
      &lt;td&gt;72 fl&lt;/td&gt;
      &lt;td&gt;(85-99)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;MCH:&lt;/td&gt;
      &lt;td&gt;25 pg&lt;/td&gt;
      &lt;td&gt;(26-34)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;MCHC:&lt;/td&gt;
      &lt;td&gt;29%&lt;/td&gt;
      &lt;td&gt;(31-37)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;RDW:&lt;/td&gt;
      &lt;td&gt;16.0&lt;/td&gt;
      &lt;td&gt;(11.5-14.5)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Platelet Count:&lt;/td&gt;
      &lt;td&gt;210,000/mm3&lt;/td&gt;
      &lt;td&gt;(170-500,000/mm3)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h3 id=&quot;wbc-differential-count&quot;&gt;WBC differential count&lt;/h3&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;Neutrophils&lt;/td&gt;
      &lt;td&gt;46%&lt;/td&gt;
      &lt;td&gt;(44-65)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Bands&lt;/td&gt;
      &lt;td&gt;4%&lt;/td&gt;
      &lt;td&gt;(0-10)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Eosinophils&lt;/td&gt;
      &lt;td&gt;5%&lt;/td&gt;
      &lt;td&gt;(0-9)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Basophils&lt;/td&gt;
      &lt;td&gt;1%&lt;/td&gt;
      &lt;td&gt;(0-4)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Monocytes&lt;/td&gt;
      &lt;td&gt;9%&lt;/td&gt;
      &lt;td&gt;(1-10)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Lymphocytes&lt;/td&gt;
      &lt;td&gt;35%&lt;/td&gt;
      &lt;td&gt;(25-46)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h3 id=&quot;what-coagulation-tests-would-you-order-and-why-look-at-the-test-results-what-is-your-interpretation-of-these-coagulation-tests-what-do-the-pfa-100-results-indicate&quot;&gt;9. What coagulation tests would you order and why? Look at the test results. What is your interpretation of these coagulation tests? What do the PFA-100 results indicate?&lt;/h3&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;Prothrombin time: 10.7 sec&lt;/td&gt;
      &lt;td&gt;(10.5-13.5 sec)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Partial thromboplastin time: 73 sec&lt;/td&gt;
      &lt;td&gt;(25.0-36.0 sec)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Bleeding time: &amp;gt;15.0 min&lt;/td&gt;
      &lt;td&gt;(2-9 min)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;PFA-100:&lt;/p&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;ADP=170 sec closure&lt;/td&gt;
      &lt;td&gt;(70-120 sec closure)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Epinephrine=270 sec closure&lt;/td&gt;
      &lt;td&gt;(89-189 sec closure)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h3 id=&quot;based-on-the-clinical-presentation-family-history-and-preliminary-laboratory-results-generate-a-differential-diagnosis-what-is-the-apparent-mode-of-inheritance&quot;&gt;10. Based on the clinical presentation, family history, and preliminary laboratory results, generate a differential diagnosis. What is the apparent mode of inheritance?&lt;/h3&gt;

&lt;h3 id=&quot;a-mixing-study-is-performed-what-information-do-you-glean-from-the-results-do-you-have-a-working-diagnosis-how-do-you-explain-the-factor-viii-level&quot;&gt;11. A mixing study is performed. What information do you glean from the results. Do you have a working diagnosis? How do you explain the factor VIII level?&lt;/h3&gt;

&lt;p&gt;Mixing study with PTT:&lt;/p&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;Dilution&lt;/td&gt;
      &lt;td&gt;Results&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;1:1, 1:4&lt;/td&gt;
      &lt;td&gt;29, 32 sec&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;Factor VIII&lt;/td&gt;
      &lt;td&gt;35%&lt;/td&gt;
      &lt;td&gt;[50-150%]&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;￼￼
### 12. Explain the following test results. Is the defect primarily of vWF quantity or quality? State the diagnosis.&lt;/p&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;von Willebrand cofactor assay&lt;/td&gt;
      &lt;td&gt;20%&lt;/td&gt;
      &lt;td&gt;[40-140%]&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;von Willebrand assay&lt;/td&gt;
      &lt;td&gt;15%&lt;/td&gt;
      &lt;td&gt;[45-180%]&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Multimer assay&lt;/td&gt;
      &lt;td&gt;Normal pattern&lt;/td&gt;
      &lt;td&gt; &lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;&lt;strong&gt;Hints:&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;von Willebrand cofactor assay=functional test 
von Willebrand assay=quantitative test&lt;/p&gt;

&lt;h3 id=&quot;von-willebrand-disease-manifests-in-several-different-types-discuss-the-three-main-types-and-decide-what-type-of-von-willebrand-disease-this-patient-has&quot;&gt;13. Von Willebrand disease manifests in several different types. Discuss the three main types and decide what type of von Willebrand disease this patient has.&lt;/h3&gt;
&lt;p&gt;￼
### 14. Describe acquired von Willebrand disease. What are the disease associations and proposed mechanisms?&lt;/p&gt;

&lt;h3 id=&quot;how-would-you-manage-this-patients-current-excessive-bleeding-what-choices-are-available-if-surgery-is-required-in-the-future&quot;&gt;15. How would you manage this patient’s current excessive bleeding? What choices are available if surgery is required in the future?&lt;/h3&gt;

&lt;h3 id=&quot;as-this-young-girl-reaches-the-age-of-60-her-bruising-may-decrease-why&quot;&gt;16. As this young girl reaches the age of 60 her bruising may decrease. Why?&lt;/h3&gt;

&lt;h3 id=&quot;why-is-the-blood-type-important-in-assessing-a-patient-for-von-willebrand-disease&quot;&gt;17. Why is the blood type important in assessing a patient for von Willebrand disease?&lt;/h3&gt;

&lt;h3 id=&quot;briefly-describe-the-subtypes-of-type-2-von-willebrand-disease&quot;&gt;18.  Briefly describe the subtypes of type 2 von Willebrand disease.&lt;/h3&gt;

&lt;h3 id=&quot;what-is-platelet-type-or-pseudo-vwd&quot;&gt;19.  What is “platelet type” or “pseudo –vWD”?&lt;/h3&gt;
</description>
        <pubDate>Mon, 05 Oct 2015 00:00:00 -0500</pubDate>
        <link>http://lanyon.getpoole.com/pathology/2015/10/05/small-group2-coagulation/</link>
        <guid isPermaLink="true">http://lanyon.getpoole.com/pathology/2015/10/05/small-group2-coagulation/</guid>
        
        <category>exam II</category>
        
        <category>pathology</category>
        
        <category>block 2</category>
        
        <category>small group 3</category>
        
        <category>WBC</category>
        
        
        <category>pathology</category>
        
      </item>
    
      <item>
        <title>WBC small group</title>
        <description>&lt;p&gt;This post is written for the small group presentation on WBC, which is from the pathology course I take at UMMC&lt;/p&gt;

&lt;!--break--&gt;

&lt;p id=&quot;beginning&quot;&gt;&lt;/p&gt;

&lt;ul id=&quot;markdown-toc&quot;&gt;
  &lt;li&gt;&lt;a href=&quot;#case-1&quot; id=&quot;markdown-toc-case-1&quot;&gt;Case 1&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#what-is-your-differential-diagnosis-after-physical-examination&quot; id=&quot;markdown-toc-what-is-your-differential-diagnosis-after-physical-examination&quot;&gt;1. What is your differential diagnosis after physical examination?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-are-some-causes-of-bone-marrow-failure&quot; id=&quot;markdown-toc-what-are-some-causes-of-bone-marrow-failure&quot;&gt;2. What are some causes of bone marrow failure?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#cbc-results&quot; id=&quot;markdown-toc-cbc-results&quot;&gt;CBC Results:&lt;/a&gt;        &lt;ul&gt;
          &lt;li&gt;&lt;a href=&quot;#differential-&quot; id=&quot;markdown-toc-differential-&quot;&gt;Differential (%)&lt;/a&gt;&lt;/li&gt;
        &lt;/ul&gt;
      &lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#describe-the-findings-in-the-complete-blood-count--is-the-patient-anemic-and-if-so-how-would-you-describe-the-anemia--is-the-patient-neutropenic--explain-how-the-absolute-neutrophil-count-is-calculated--what-is-the-significance-of-neutropenia&quot; id=&quot;markdown-toc-describe-the-findings-in-the-complete-blood-count--is-the-patient-anemic-and-if-so-how-would-you-describe-the-anemia--is-the-patient-neutropenic--explain-how-the-absolute-neutrophil-count-is-calculated--what-is-the-significance-of-neutropenia&quot;&gt;3. Describe the findings in the complete blood count.  Is the patient anemic, and if so, how would you describe the anemia?  Is the patient neutropenic?  Explain how the absolute neutrophil count is calculated.  What is the significance of neutropenia?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#examine-the-peripheral-smear-and-describe-the-cells--what-are-these-cells-and-what-do-they-indicate&quot; id=&quot;markdown-toc-examine-the-peripheral-smear-and-describe-the-cells--what-are-these-cells-and-what-do-they-indicate&quot;&gt;4. Examine the peripheral smear and describe the cells.  What are these cells and what do they indicate?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-are-common-leukemias-that-afflict-children&quot; id=&quot;markdown-toc-what-are-common-leukemias-that-afflict-children&quot;&gt;5. What are common leukemias that afflict children?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-information-do-you-glean-from-these-cytochemical-stains&quot; id=&quot;markdown-toc-what-information-do-you-glean-from-these-cytochemical-stains&quot;&gt;6. What information do you glean from these cytochemical stains?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#more-description-for-patient&quot; id=&quot;markdown-toc-more-description-for-patient&quot;&gt;more description for patient&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#explain-the-flow-cytometry-results--how-do-immunophenotyping-studies-flow-cytometry-help-determine-the-diagnosis--refer-to-the-chart-of-lymphocyte-maturation-next-slide-for-a-reference&quot; id=&quot;markdown-toc-explain-the-flow-cytometry-results--how-do-immunophenotyping-studies-flow-cytometry-help-determine-the-diagnosis--refer-to-the-chart-of-lymphocyte-maturation-next-slide-for-a-reference&quot;&gt;7. Explain the flow cytometry results.  How do immunophenotyping studies (flow cytometry) help determine the diagnosis?  Refer to the chart of lymphocyte maturation (next slide) for a reference.&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-do-you-see-in-the-bone-marrow-biopsy&quot; id=&quot;markdown-toc-what-do-you-see-in-the-bone-marrow-biopsy&quot;&gt;8. What do you see in the bone marrow biopsy?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-is-the-prognosis-for-this-patient-based-on-wbc-age-and-gender--describe-favorable-and-unfavorable-cytogenetic-findings-for-patients-with-all&quot; id=&quot;markdown-toc-what-is-the-prognosis-for-this-patient-based-on-wbc-age-and-gender--describe-favorable-and-unfavorable-cytogenetic-findings-for-patients-with-all&quot;&gt;9.  What is the prognosis for this patient based on WBC, age, and gender?  Describe favorable and unfavorable cytogenetic findings for patients with ALL.&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#the-patient-is-treated-with-chemotherapy-including-vincristine-prednisone-and-l-asparaginase-with-intrathecal-methotrexate-mtx--why-is-intrathecal-treatment-indicated&quot; id=&quot;markdown-toc-the-patient-is-treated-with-chemotherapy-including-vincristine-prednisone-and-l-asparaginase-with-intrathecal-methotrexate-mtx--why-is-intrathecal-treatment-indicated&quot;&gt;10. The patient is treated with chemotherapy including vincristine, prednisone, and L-asparaginase with intrathecal methotrexate (MTX).  Why is intrathecal treatment indicated?&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#case-2&quot; id=&quot;markdown-toc-case-2&quot;&gt;Case 2&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#case-history&quot; id=&quot;markdown-toc-case-history&quot;&gt;Case History&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#cbc-results-1&quot; id=&quot;markdown-toc-cbc-results-1&quot;&gt;CBC Results:&lt;/a&gt;        &lt;ul&gt;
          &lt;li&gt;&lt;a href=&quot;#wbc-differential-&quot; id=&quot;markdown-toc-wbc-differential-&quot;&gt;WBC Differential (%)&lt;/a&gt;&lt;/li&gt;
        &lt;/ul&gt;
      &lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#questions&quot; id=&quot;markdown-toc-questions&quot;&gt;QUESTIONS&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-does-the-cbc-reveal&quot; id=&quot;markdown-toc-what-does-the-cbc-reveal&quot;&gt;11. What does the CBC reveal?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#examine-the-peripheral-smear--describe-your-findings-particularly-the-nuclear-features-of-the-neutrophils--what-is-this-phenomenon-called-and-when-may-it-be-seen&quot; id=&quot;markdown-toc-examine-the-peripheral-smear--describe-your-findings-particularly-the-nuclear-features-of-the-neutrophils--what-is-this-phenomenon-called-and-when-may-it-be-seen&quot;&gt;12. Examine the peripheral smear.  Describe your findings, particularly the nuclear features of the neutrophils.  What is this phenomenon called and when may it be seen?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-is-your-differential-diagnosis&quot; id=&quot;markdown-toc-what-is-your-differential-diagnosis&quot;&gt;13. What is your differential diagnosis?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-is-the-next-diagnostic-test-which-should-be-performed-and-why&quot; id=&quot;markdown-toc-what-is-the-next-diagnostic-test-which-should-be-performed-and-why&quot;&gt;14. What is the next diagnostic test which should be performed and why?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#examine-the-bone-marrow-aspirate-and-biopsy-slides-2-5--describe-your-findings--what-are-typical-marrow-findings-in-myelodysplastic-syndromes&quot; id=&quot;markdown-toc-examine-the-bone-marrow-aspirate-and-biopsy-slides-2-5--describe-your-findings--what-are-typical-marrow-findings-in-myelodysplastic-syndromes&quot;&gt;15. Examine the bone marrow aspirate and biopsy (slides 2-5).  Describe your findings.  What are typical marrow findings in myelodysplastic syndromes?&lt;/a&gt;        &lt;ul&gt;
          &lt;li&gt;&lt;a href=&quot;#bone-marrow-aspirate-and-biopsy-slides-2-5-for-case-2&quot; id=&quot;markdown-toc-bone-marrow-aspirate-and-biopsy-slides-2-5-for-case-2&quot;&gt;bone marrow aspirate and biopsy (slides 2-5) for case 2&lt;/a&gt;&lt;/li&gt;
        &lt;/ul&gt;
      &lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#describe-low-and-high-grade-myelodysplastic-syndromes-in-terms-of-marrow-cellularity&quot; id=&quot;markdown-toc-describe-low-and-high-grade-myelodysplastic-syndromes-in-terms-of-marrow-cellularity&quot;&gt;16. Describe low and high-grade myelodysplastic syndromes in terms of marrow cellularity.&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-is-aleukemic-leukemia&quot; id=&quot;markdown-toc-what-is-aleukemic-leukemia&quot;&gt;17. What is aleukemic leukemia?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-findings-might-you-expect-on-a-karyotyping-study-of-the-marrow-in-mds--what-is-the-most-common-cytogenetic-abnormality-in-acute-myeloid-leukemia&quot; id=&quot;markdown-toc-what-findings-might-you-expect-on-a-karyotyping-study-of-the-marrow-in-mds--what-is-the-most-common-cytogenetic-abnormality-in-acute-myeloid-leukemia&quot;&gt;18. What findings might you expect on a karyotyping study of the marrow in MDS?  What is the most common cytogenetic abnormality in acute myeloid leukemia?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-is-the-prognosis-for-mds--describe-treatments-for-myelodysplastic-syndrome--what-are-causes-of-death-in-myelodysplastic-syndrome&quot; id=&quot;markdown-toc-what-is-the-prognosis-for-mds--describe-treatments-for-myelodysplastic-syndrome--what-are-causes-of-death-in-myelodysplastic-syndrome&quot;&gt;19. What is the prognosis for MDS?  Describe treatments for myelodysplastic syndrome.  What are causes of death in myelodysplastic syndrome?&lt;/a&gt;        &lt;ul&gt;
          &lt;li&gt;&lt;a href=&quot;#prognosis&quot; id=&quot;markdown-toc-prognosis&quot;&gt;prognosis&lt;/a&gt;&lt;/li&gt;
          &lt;li&gt;&lt;a href=&quot;#cause-of-death&quot; id=&quot;markdown-toc-cause-of-death&quot;&gt;cause of death&lt;/a&gt;&lt;/li&gt;
          &lt;li&gt;&lt;a href=&quot;#treatment&quot; id=&quot;markdown-toc-treatment&quot;&gt;treatment&lt;/a&gt;&lt;/li&gt;
        &lt;/ul&gt;
      &lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h2 id=&quot;case-1&quot;&gt;Case 1&lt;/h2&gt;

&lt;h3 id=&quot;what-is-your-differential-diagnosis-after-physical-examination&quot;&gt;1. What is your differential diagnosis after physical examination?&lt;/h3&gt;

&lt;h3 id=&quot;what-are-some-causes-of-bone-marrow-failure&quot;&gt;2. What are some causes of bone marrow failure?&lt;/h3&gt;

&lt;h3 id=&quot;cbc-results&quot;&gt;CBC Results:&lt;/h3&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;patient&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Reference Interval&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;WBC=9,000/mm3&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(4000-11,000/mm3)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;HGB=9 g/dL&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(12-15 g/dL)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;HCT=27%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(31-43%)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;MCV=86 fL&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(80-99 fL)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;MCHC=32%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(31-37%)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;RDW=13.0&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(11.5-14.5)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;PLATELETS=55,000/mm3&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(130-400,000/mm3)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h4 id=&quot;differential-&quot;&gt;Differential (%)&lt;/h4&gt;

&lt;p&gt;5 segmented neutrophils, 15 lymphocytes, 5 monocytes, 75 blasts.&lt;/p&gt;

&lt;h3 id=&quot;describe-the-findings-in-the-complete-blood-count--is-the-patient-anemic-and-if-so-how-would-you-describe-the-anemia--is-the-patient-neutropenic--explain-how-the-absolute-neutrophil-count-is-calculated--what-is-the-significance-of-neutropenia&quot;&gt;3. Describe the findings in the complete blood count.  Is the patient anemic, and if so, how would you describe the anemia?  Is the patient neutropenic?  Explain how the absolute neutrophil count is calculated.  What is the significance of neutropenia?&lt;/h3&gt;

&lt;h3 id=&quot;examine-the-peripheral-smear-and-describe-the-cells--what-are-these-cells-and-what-do-they-indicate&quot;&gt;4. Examine the peripheral smear and describe the cells.  What are these cells and what do they indicate?&lt;/h3&gt;

&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/smallGroup/WBC/1.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/smallGroup/WBC/1.jpeg&quot; alt=&quot;slide1&quot; width=&quot;180&quot; height=&quot;150&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Peripheral blood smear with lymphoblasts  &lt;/div&gt;
&lt;/div&gt;

&lt;h3 id=&quot;what-are-common-leukemias-that-afflict-children&quot;&gt;5. What are common leukemias that afflict children?&lt;/h3&gt;

&lt;h3 id=&quot;what-information-do-you-glean-from-these-cytochemical-stains&quot;&gt;6. What information do you glean from these cytochemical stains?&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Sudan black B and myeloperoxidase - negative in blasts, positive in normal neutrophils&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;PAS - block positivity in blasts (see figure below)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Specific and non-specific esterases - negative in blasts&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/smallGroup/WBC/2.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/smallGroup/WBC/2.jpeg&quot; alt=&quot;slide2&quot; width=&quot;180&quot; height=&quot;150&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Lymphoblasts with characteristic “block” or globular PAS positivity &lt;/div&gt;
&lt;/div&gt;

&lt;h3 id=&quot;more-description-for-patient&quot;&gt;more description for patient&lt;/h3&gt;

&lt;p&gt;The lab calls you with the CBC results as the patient is being taken to Radiology.  At this point, you decide a bone marrow biopsy is more important than the X-ray and call the patient back for a marrow biopsy, sending an aspirate to the Immunopathology Lab for flow cytometry immunophenotyping of the blasts.&lt;/p&gt;

&lt;h3 id=&quot;explain-the-flow-cytometry-results--how-do-immunophenotyping-studies-flow-cytometry-help-determine-the-diagnosis--refer-to-the-chart-of-lymphocyte-maturation-next-slide-for-a-reference&quot;&gt;7. Explain the flow cytometry results.  How do immunophenotyping studies (flow cytometry) help determine the diagnosis?  Refer to the chart of lymphocyte maturation (next slide) for a reference.&lt;/h3&gt;

&lt;p&gt;CD45  leukocyte common antigen (LCA)
CD34  CD117 - blast/stem cell marker
HLA-DR  (early myeloid and B-cells)
TdT (lymphoid)
CD 10,19,20 are positive, indicates lymphoid (B-lineage) 
CD2,3,5 are negatives, rule out peripheral T-cell lymphomas -lymphoid (T-lineage)&lt;/p&gt;

&lt;p&gt;kappa and lambda are negative - rule out Plasma Cell Neoplasms and Related Disorders&lt;/p&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;CD45&lt;/td&gt;
      &lt;td&gt;positive&lt;/td&gt;
      &lt;td&gt;Surface kappa&lt;/td&gt;
      &lt;td&gt;negative&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;CD34&lt;/td&gt;
      &lt;td&gt;negative&lt;/td&gt;
      &lt;td&gt;Surface lambda&lt;/td&gt;
      &lt;td&gt;negative&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;HLA-DR&lt;/td&gt;
      &lt;td&gt;positive&lt;/td&gt;
      &lt;td&gt;CD2&lt;/td&gt;
      &lt;td&gt;negative&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;TdT&lt;/td&gt;
      &lt;td&gt;positive&lt;/td&gt;
      &lt;td&gt;CD3&lt;/td&gt;
      &lt;td&gt;negative&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;CD20&lt;/td&gt;
      &lt;td&gt;positive&lt;/td&gt;
      &lt;td&gt;CD5&lt;/td&gt;
      &lt;td&gt;negative&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;CD19&lt;/td&gt;
      &lt;td&gt;positive&lt;/td&gt;
      &lt;td&gt;CD10&lt;/td&gt;
      &lt;td&gt;positive&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/smallGroup/WBC/3.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/smallGroup/WBC/3.jpeg&quot; alt=&quot;slide3&quot; width=&quot;180&quot; height=&quot;150&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Lymphocyte development (B and T)&lt;/div&gt;
&lt;/div&gt;

&lt;h3 id=&quot;what-do-you-see-in-the-bone-marrow-biopsy&quot;&gt;8. What do you see in the bone marrow biopsy?&lt;/h3&gt;

&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/smallGroup/WBC/4.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/smallGroup/WBC/4.jpeg&quot; alt=&quot;slide4&quot; width=&quot;180&quot; height=&quot;150&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;
		normal &lt;/div&gt;
&lt;/div&gt;

&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/smallGroup/WBC/5.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/smallGroup/WBC/5.jpeg&quot; alt=&quot;slide4&quot; width=&quot;180&quot; height=&quot;150&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;
	 acute leukemia &lt;/div&gt;
&lt;/div&gt;

&lt;h3 id=&quot;what-is-the-prognosis-for-this-patient-based-on-wbc-age-and-gender--describe-favorable-and-unfavorable-cytogenetic-findings-for-patients-with-all&quot;&gt;9.  What is the prognosis for this patient based on WBC, age, and gender?  Describe favorable and unfavorable cytogenetic findings for patients with ALL.&lt;/h3&gt;

&lt;p&gt;B-ALL
Children: 95% remission; 80% appear to be cured.&lt;/p&gt;

&lt;p&gt;11 q23&lt;/p&gt;

&lt;p&gt;Adults: 60-85% remission. Genetics not as well characterized as in children (25% have Ph1 chromosome.
B-LBL
High remission rate. Median survival 5 years&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;#beginning&quot;&gt;back to the top&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;the-patient-is-treated-with-chemotherapy-including-vincristine-prednisone-and-l-asparaginase-with-intrathecal-methotrexate-mtx--why-is-intrathecal-treatment-indicated&quot;&gt;10. The patient is treated with chemotherapy including vincristine, prednisone, and L-asparaginase with intrathecal methotrexate (MTX).  Why is intrathecal treatment indicated?&lt;/h3&gt;

&lt;p&gt;a lot of chemo drugs don’t pass the brain blood barrior. so it needs Intrathecal therapy&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a. What is the mechanism of the chemotherapeutic agents in general?&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;targeting rapidly deviding cells&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;b. With what enzyme does methotrexate (MTX) interfere?&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;dihydrofolate reductase&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;c. What is complete remission (CR)?&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;dispearance of signs of cancer cells&lt;/p&gt;

&lt;p&gt;the blast number should be at 5% or less&lt;/p&gt;

&lt;h2 id=&quot;case-2&quot;&gt;Case 2&lt;/h2&gt;

&lt;h3 id=&quot;case-history&quot;&gt;Case History&lt;/h3&gt;

&lt;p&gt;The patient is a 77 year-old man with &lt;strong&gt;extreme fatigue and malaise&lt;/strong&gt;.  He saw a doctor at a walk-in clinic seven months ago for similar complaints.  He shows you the prescription given to him then, which he has faithfully taken.  It is a &lt;strong&gt;multivitamin with iron&lt;/strong&gt;.  He is on no other medications.  He is thin, but not cachectic and he appears tired.&lt;/p&gt;

&lt;p&gt;No abnormalities are found on physical exam except for &lt;strong&gt;petechiae&lt;/strong&gt;, a few &lt;strong&gt;bruises&lt;/strong&gt; on his lower legs, &lt;strong&gt;pallor and pale mucous membranes&lt;/strong&gt;.  The digital rectal exam shows no enlargement of the prostate gland and the stool guaiac test is negative for occult blood.  You send a blood sample in a purple top (EDTA) tube for a CBC with reticulocyte count.&lt;/p&gt;

&lt;h3 id=&quot;cbc-results-1&quot;&gt;CBC Results:&lt;/h3&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;patient&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Reference Interval&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;WBC=1,180/mm&lt;sup&gt;3&lt;/sup&gt;&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(4000-11,000/mm&lt;sup&gt;3&lt;/sup&gt;)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;HGB=10 g/dL&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(14-18 g/dL)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;HCT=30%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(42-49%)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;MCV=103 fL&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(80-99 fL)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;MCHC=33 g/dL&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(31-37 g/dL)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;RDW=20&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(11.5-14.5)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;PLATELETS=50,000/mm3&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(130,-400,000/mm3)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;RETICULOCYTE (%)=0.1 %&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(0.5-1.5%, manual)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h4 id=&quot;wbc-differential-&quot;&gt;WBC Differential (%)&lt;/h4&gt;

&lt;p&gt;65 segs, 30 lymphocytes, 5 monocytes&lt;/p&gt;

&lt;h3 id=&quot;questions&quot;&gt;QUESTIONS&lt;/h3&gt;

&lt;h3 id=&quot;what-does-the-cbc-reveal&quot;&gt;11. What does the CBC reveal?&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;low htc (anemia), low WBC(pan-cytopenias),low platelets indicates haematopoiesis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;high MCV &amp;gt;100fL (macrocytosis), the multivitamin given previously was for B12 deficiency.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Abnormal RBC maturation (eg, myelodysplastic syndrome, acute leukemia, LGL leukemia)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;low reticulocyte (either it is not produced, the &lt;strong&gt;bone marrow&lt;/strong&gt; is not functioning)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;WEB differential does not mention any blast.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;examine-the-peripheral-smear--describe-your-findings-particularly-the-nuclear-features-of-the-neutrophils--what-is-this-phenomenon-called-and-when-may-it-be-seen&quot;&gt;12. Examine the peripheral smear.  Describe your findings, particularly the nuclear features of the neutrophils.  What is this phenomenon called and when may it be seen?&lt;/h3&gt;

&lt;p&gt;neutrophils appear bilobed, indicative of Pelger-Huet anomaly. It may be seen in Myelodysplastic Syndromes&lt;/p&gt;

&lt;p&gt;note: when seeing hypersegmented nutrophils, think of B12 deficiency&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;/assets/pathology/smallGroup/WBC/6.jpeg&quot; alt=&quot;Peripheral blood film&quot; /&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-is-your-differential-diagnosis&quot;&gt;13. What is your differential diagnosis?&lt;/h3&gt;

&lt;p&gt;old age, fatigue, anemia , pallor and pale mucous membranes,&lt;/p&gt;

&lt;p&gt;bruise and petechiae assoicated with low platelets count (thrombocytopenia.)&lt;/p&gt;

&lt;p&gt;Pelger-Huet anomaly&lt;/p&gt;

&lt;p&gt;low htc, low WBC(pan-cytopenias),low platelets indicates haematopoiesis&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;note&lt;/strong&gt; patient previous was given iron treatment, and he did not response to it.&lt;/p&gt;

&lt;p&gt;also consider drug toxicity&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-next-diagnostic-test-which-should-be-performed-and-why&quot;&gt;14. What is the next diagnostic test which should be performed and why?&lt;/h3&gt;

&lt;p&gt;&lt;a href=&quot;http://www.cancer.org/cancer/myelodysplasticsyndrome/detailedguide/myelodysplastic-syndromes-diagnosis&quot;&gt;Bone marrow tests&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;trilineage of the cells&lt;/p&gt;

&lt;p&gt;aspirate provides morphological features and architecture of the cells.&lt;/p&gt;

&lt;p&gt;adjust cellularity&lt;/p&gt;

&lt;p&gt;send to cytogenetic for abnormality&lt;/p&gt;

&lt;p&gt;and float cytometry&lt;/p&gt;

&lt;p&gt;These tests are used first for diagnosis and classification and may be repeated later to tell if the MDS is responding to therapy or is transforming into an acute leukemia.&lt;/p&gt;

&lt;h3 id=&quot;examine-the-bone-marrow-aspirate-and-biopsy-slides-2-5--describe-your-findings--what-are-typical-marrow-findings-in-myelodysplastic-syndromes&quot;&gt;15. Examine the bone marrow aspirate and biopsy (slides 2-5).  Describe your findings.  What are typical marrow findings in myelodysplastic syndromes?&lt;/h3&gt;

&lt;p&gt;1 Bone marrow biopsy showed 100% cellularity (hypercellularity) with erythroid predominance and granulocytic and megakaryocytic dyspoiesis&lt;/p&gt;

&lt;p&gt;2 dysplastic red cell precursors manifested by abnormal nuclear contours, nuclear budding, and other abnormalities of nuclei&lt;/p&gt;

&lt;p&gt;dysmegakaryopoiesis, erythoroid precursor.&lt;/p&gt;

&lt;p&gt;3 Significant erythroid predominance with dyserythropoiesis and with &lt;strong&gt;Auer rod&lt;/strong&gt;. (confirmed it is AML)&lt;/p&gt;

&lt;p&gt;large N/C ratio. has large cytoplasm.&lt;/p&gt;

&lt;p&gt;4 Hypercellular bone marrow with dysmegakaryopoiesis.&lt;/p&gt;

&lt;h4 id=&quot;bone-marrow-aspirate-and-biopsy-slides-2-5-for-case-2&quot;&gt;bone marrow aspirate and biopsy (slides 2-5) for case 2&lt;/h4&gt;

&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/smallGroup/WBC/7.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/smallGroup/WBC/7.jpeg&quot; alt=&quot;slide2&quot; width=&quot;180&quot; height=&quot;150&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Bone marrow biopsy with predominance of blasts &lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/smallGroup/WBC/8.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/smallGroup/WBC/8.jpeg&quot; alt=&quot;slide3&quot; width=&quot;180&quot; height=&quot;150&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Marked dyserythropoiesis in marrow&lt;/div&gt;
&lt;/div&gt;

&lt;p&gt;Prominent erythroid dysplasia and rare dysplastic granulocytic precursors&lt;/p&gt;

&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/smallGroup/WBC/9.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/smallGroup/WBC/9.jpeg&quot; alt=&quot;slide4&quot; width=&quot;180&quot; height=&quot;150&quot; /&gt;
  &lt;/a&gt;
   &lt;div class=&quot;desc&quot;&gt;Cluster of myeloblasts—one has an Auer rod&lt;/div&gt;



&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/smallGroup/WBC/10.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/smallGroup/WBC/10.jpeg&quot; alt=&quot;slide5&quot; width=&quot;180&quot; height=&quot;150&quot; /&gt;
  &lt;/a&gt;
    &lt;div class=&quot;desc&quot;&gt;Marrow depicting abnormal localization of immature precursors&lt;/div&gt;
&lt;/div&gt;
&lt;p&gt;Lymphoid aggregate in a background of hypercellular bone marrow.&lt;/p&gt;

&lt;h3 id=&quot;describe-low-and-high-grade-myelodysplastic-syndromes-in-terms-of-marrow-cellularity&quot;&gt;16. Describe low and high-grade myelodysplastic syndromes in terms of marrow cellularity.&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;progress slowly and may cause mild to moderate anemia (a low number of red cells), or decrements to other types of cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;higher blast counts and more severe cytopenias, as well as the presence of multiple clonal chromosomal abnormalities.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;em&gt;additional information&lt;/em&gt; (see &lt;a href=&quot;http://www.hopkinsmedicine.org/kimmel_cancer_center/types_cancer/myelodysplastic_syndrome.html&quot;&gt;source here&lt;/a&gt;)&lt;/p&gt;

&lt;p&gt;grade 1&lt;/p&gt;

&lt;p&gt;5%  to 9%&lt;/p&gt;

&lt;p&gt;grade 2
10% to 19%&lt;/p&gt;

&lt;p&gt;if auer rod is present, it is considered grade 2&lt;/p&gt;

&lt;p&gt;&lt;em&gt;immature cells called blast cells make up more than 5 percent of the cells in the marrow.&lt;/em&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;When MDS patients develop more than 20 percent blast cells, they are reclassified as having acute myelogenous leukemia (AML)*&lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;what-is-aleukemic-leukemia&quot;&gt;17. What is aleukemic leukemia?&lt;/h3&gt;

&lt;p&gt;blasts are entirely absent from the blood (aleukemic leukemia).&lt;/p&gt;

&lt;p&gt;can happen in any of the 4 major leukemias.&lt;/p&gt;

&lt;h3 id=&quot;what-findings-might-you-expect-on-a-karyotyping-study-of-the-marrow-in-mds--what-is-the-most-common-cytogenetic-abnormality-in-acute-myeloid-leukemia&quot;&gt;18. What findings might you expect on a karyotyping study of the marrow in MDS?  What is the most common cytogenetic abnormality in acute myeloid leukemia?&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Monosomies 5 and 7&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Deletions of 5q, 7q, and 20q&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Trisomy 8&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;deletion 5q isolation, has better pronosis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;7 q is worse&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;what-is-the-prognosis-for-mds--describe-treatments-for-myelodysplastic-syndrome--what-are-causes-of-death-in-myelodysplastic-syndrome&quot;&gt;19. What is the prognosis for MDS?  Describe treatments for myelodysplastic syndrome.  What are causes of death in myelodysplastic syndrome?&lt;/h3&gt;

&lt;h4 id=&quot;prognosis&quot;&gt;prognosis&lt;/h4&gt;

&lt;p&gt;The median survival in primary MDS varies from 9 to 29 months, but some individuals in good prognostic groups may live for 5 years or more.&lt;/p&gt;

&lt;p&gt;Overall, progression to AML occurs in 10% to 40% of individuals and is usually accompanied by the appearance of additional cytogenetic abnormalities.&lt;/p&gt;

&lt;h4 id=&quot;cause-of-death&quot;&gt;cause of death&lt;/h4&gt;

&lt;p&gt;Patients often succumb to the complications of thrombocytopenia (bleeding) and neutropenia (infection). The outlook is even grimmer in t-MDS, which has a median survival of only 4 to 8 months. &lt;strong&gt;bleeding is the major cause&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;In t-MDS, cytopenias tend to be more severe and progression to AML is often rapid.&lt;/p&gt;

&lt;h4 id=&quot;treatment&quot;&gt;treatment&lt;/h4&gt;

&lt;ul&gt;
  &lt;li&gt;In younger patients&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;allogeneic hematopoietic stem cell transplantation offers hope for reconstitution of normal hematopoiesis and possible cure.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Older patients&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Supportively with antibiotics and blood product transfusions.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Thalidomide-like drugs&lt;/strong&gt; and DNA methylation inhibitors improve the effectiveness of hematopoiesis and the peripheral blood counts in a subset of patients. (no longer use)&lt;/p&gt;

&lt;p&gt;The presence of isolated 5q- is correlated with a hematologic response to thalidomide-like drugs, but as yet response to DNA methylation inhibitors is unpredictable.&lt;/p&gt;
</description>
        <pubDate>Mon, 05 Oct 2015 00:00:00 -0500</pubDate>
        <link>http://lanyon.getpoole.com/pathology/2015/10/05/small-group-wbc/</link>
        <guid isPermaLink="true">http://lanyon.getpoole.com/pathology/2015/10/05/small-group-wbc/</guid>
        
        <category>exam II</category>
        
        <category>pathology</category>
        
        <category>block 2</category>
        
        <category>small group</category>
        
        <category>WBC</category>
        
        
        <category>pathology</category>
        
      </item>
    
  </channel>
</rss>
